Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 51
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Reversion of metabolic dysfunction-associated steatohepatitis by skeletal muscle-directed FGF21 gene therapy

  • Jimenez, Veronica|||0000-0001-9145-9877
  • Sacristan, Victor|||0000-0003-0356-0356
  • Jambrina Pallarés, Claudia|||0000-0002-9093-5568
  • Jaén Sitges, Maria Luisa|||0000-0002-9188-0810
  • Casaña Lorente, Estefania|||0000-0002-1353-5018
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Marcó, Sara|||0000-0003-3502-5198
  • Molas Laplana, Maria|||0000-0002-3215-515X
  • Garcia, Miquel|||0000-0002-1602-4993
  • Grass Costa, Ignasi|||0000-0002-6917-3271
  • León, Xavier|||0000-0002-8393-2721
  • Elias Puigdomenech, Ivet|||0000-0002-1304-9597
  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Elias Bosch, Gemma|||0000-0003-1985-7955
  • Sánchez Clares, Víctor|||0000-0001-8631-9239
  • Vilà, Laia|||0000-0002-1211-5804
  • Casellas Comallonga, Alba|||0000-0003-0203-4733
  • Ferre, Tura|||0000-0001-9713-0829
  • Rodó Morera, Jordi|||0000-0001-8533-2597
  • Carretero i Romay, Ana|||0000-0001-9377-4926
  • Pumarola i Batlle, Martí|||0000-0002-0935-7941
  • Navarro Beltrán, Marc|||0000-0002-9678-6129
  • Andaluz Martínez, Anna|||0000-0001-8097-8110
  • Moll, Xavier|||0000-0002-2992-9361
  • Añor Torres, Sònia|||0000-0002-1099-7698
  • Franckhauser, Sylvie|||0000-0001-5255-1224
  • Vergara, Mercedes|||0000-0002-6971-8657
  • Caixàs i Pedragós, Assumpta|||0000-0001-8472-9189
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
The highly prevalent metabolic dysfunction-associated steatohepatitis (MASH) is associated with liver steatosis, inflammation, and hepatocyte injury, which can lead to fibrosis and may progress to hepatocellular carcinoma and death. New treatment modalities such as gene therapy may be transformative for MASH patients. Here, we describe that one-time intramuscular administration of adeno-associated viral vectors of serotype 1 (AAV1) encoding native fibroblast growth factor 21 (FGF21), a key metabolic regulator, resulted in sustained increased circulating levels of the factor, which mediated long-term (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy

  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Bertolín Gálvez, Joan|||0000-0002-5196-0955
  • Jimenez, Veronica|||0000-0001-9145-9877
  • Jaén Sitges, Maria Luisa|||0000-0002-9188-0810
  • Garcia, Miquel|||0000-0002-1602-4993
  • Pujol i Altarriba, Anna|||0000-0002-3484-598X
  • Vilà, Laia|||0000-0002-1211-5804
  • Sacristan, Victor|||0000-0003-0356-0356
  • Barbon, Elena
  • Ronzitti, Giuseppe
  • Andari, Jihad El
  • Tulalamba, Warut
  • Pham, Quang Hong
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • VandenDriessche, Thierry
  • Chuah, Marinee K.
  • Grimm, Dirk
  • Mingozzi, Federico
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Objective: Pompe disease (PD) is caused by deficiency of the lysosomal enzyme acid α-glucosidase (GAA), leading to progressive glycogen accumulation and severe myopathy with progressive muscle weakness. In the Infantile-Onset PD (IOPD), death generally occurs <1 year of age. There is no cure for IOPD. Mouse models of PD do not completely reproduce human IOPD severity. Our main objective was to generate the first IOPD rat model to assess an innovative muscle-directed adeno-associated viral (AAV) vector-mediated gene therapy. Methods: PD rats were generated by CRISPR/Cas9 technology. The novel highly myotropic bioengineered capsid AAVMYO3 and an optimized muscle-specific promoter in conjunction with a transcriptional cis-regulatory element were used to achieve robust Gaa expression in the entire muscular system. Several metabolic, molecular, histopathological, and functional parameters were measured. Results: PD rats showed early-onset widespread glycogen accumulation, hepato- and cardiomegaly, decreased body and tissue weight, severe impaired muscle function and decreased survival, closely resembling human IOPD. Treatment with AAVMYO3-Gaa vectors resulted in widespread expression of Gaa in muscle throughout the body, normalizing glycogen storage pathology, restoring muscle mass and strength, counteracting cardiomegaly and normalizing survival rate. Conclusions: This gene therapy holds great potential to treat glycogen metabolism alterations in IOPD. Moreover, the AAV-mediated approach may be exploited for other inherited muscle diseases, which also are limited by the inefficient widespread delivery of therapeutic transgenes throughout the muscular system.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rat models of musculoskeletal lysosomal storage disorders and their role in pre-clinical evaluation of gene therapy approaches

  • Marcó, Sara|||0000-0003-3502-5198
  • Muñoz Forero, Sergio Antonio|||0000-0001-6641-5004
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
  • Jimenez, Veronica|||0000-0001-9145-9877
Mice have been a cornerstone of biomedical research for decades for studying a wide range of biological processes, disease mechanisms, and the assessment of therapies. Moreover, mice present several practical advantages such as small size, low cost and ease of genetic manipulation. While mice offer numerous benefits, for certain disease areas, rat models provide a closer representation of human disease progression, offering better insights for translational research and therapeutic development. This closer resemblance is particularly important for research focusing on diseases involving the cardiovascular and musculoskeletal system. In rats, the pathophysiology of these diseases mirrors the clinical alterations observed in humans. This review focuses on the key phenotypic differences between mouse and rat models of lysosomal storage disorders that specifically manifest with cardiac, skeletal muscle, and bone and joint involvement (Pompe and Danon diseases, and Maroteaux-Lamy and Morquio A syndromes). Furthermore, we discuss the therapeutic potential of various adeno-associated viral vector-mediated gene therapies that have been evaluated in these rat models, highlighting their contributions to advancing treatment options for these debilitating conditions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Network analysis of influential risk factors in adolescent suicide attempters

  • Fernandez-Fernandez, Jennifer
  • Jiménez-Treviño, Luis|||0000-0002-9551-8587
  • Andreo Jover, Jorge|||0000-0002-6703-8017
  • Ayad-Ahmed, Wala|||0000-0002-0786-0076
  • Bobes-Bascarán, Maria T.|||0000-0002-5279-504X
  • Canal-Rivero, Manuel|||0000-0002-5818-5103
  • Cebrià, Ana Isabel|||0000-0002-2632-8130
  • Crespo-Facorro, Benedicto|||0000-0003-0033-7132
  • Torre-Luque, Alejandro de la|||0000-0003-0595-6127
  • Díaz-Marsá, Marina|||0000-0003-1364-3163
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Gómez Vallejo, Sandra|||0000-0003-0963-6585
  • Grande, Iria|||0000-0002-0137-0666
  • Iglesias, Noelia
  • Ortin, Francisco
  • March, Katya B.
  • Palao Tarrero, Ángela|||0000-0003-2717-5807
  • Pérez-Díez, Iván|||0000-0002-9972-2825
  • Pérez-Guerra, Carla
  • Ruiz-Veguilla, Miguel|||0000-0002-5790-7346
  • Vieta, Eduard|||0000-0002-0548-0053
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Sáiz, Pilar A.|||0000-0002-5705-4523
Objective: This study aims to investigate the interrelationship of risk factors for suicidal behaviour and their influence on attempt severity in a sample of adolescents who have recently attempted suicide. For it a network analyse was performed. Method: Data from a sample of adolescents from 12 to 17 years of age with documented suicide attempts were collected and analysed in the context of a larger study conducted in Spain called SURVIVE. Several factors were examined including age, sex, depression, trauma, impulsivity, and substance abuse. Graph analysis was performed to identify relationships and centrality measures among these factors. Results: A total of 267 participants were enrolled: 233 females and 34 males with a mean age of 15.00 years (SD = 1.52). The results indicate that age and sex do not have a notable relationship with attempt severity in adolescents. Emotional and behavioural difficulties, measured by the Strengths and Difficulties Questionnaire (SDQ), have the greatest influence on other variables. Depression and childhood trauma show varying degrees of association with suicidal behaviour, as does motor impulsivity. Substance use does not appear to be strongly related to suicide attempt severity. The number of suicide attempts is strongly correlated with emotional and behavioural difficulties, depression, and childhood trauma. Lethality of suicide attempts and intensity of suicidal ideation do not show significant associations with the other variables. Conclusion: This study identifies significant risk factors for adolescent suicide. Emotional and behavioural symptoms, depression, and childhood trauma are strongly linked to suicidal behaviour. However, age, sex, and substance abuse show minimal correlation. Assessing emotional difficulties and depressive symptoms using specific questionnaires could be crucial in evaluating suicidal behaviour in adolescents.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer

  • Maxwell, Christopher|||0000-0002-0713-7136
  • Benítez, Javier J.
  • Gómez-Baldó, Laia
  • Osorio, Ana|||0000-0001-8124-3984
  • Bonifaci, Núria|||0000-0002-8193-6825
  • Fernández-Ramires, Ricardo|||0000-0002-6974-2593
  • Costes, Sylvain|||0000-0002-8542-2389
  • Guinó, Elisabet|||0000-0003-0093-2652
  • Chen, Helen
  • Evans, Gareth|||0000-0002-8482-5784
  • Mohan, Pooja
  • Català, Isabel
  • Petit Montserrat, Anna|||0000-0002-9284-095X
  • Aguilar, Helena
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Aytes, Alvaro|||0000-0003-0725-5340
  • Serra-Musach, Jordi
  • Rennert, Gad|||0000-0002-8512-068X
  • Lejbkowicz, Flavio|||0000-0001-5718-0418
  • Peterlongo, Paolo|||0000-0001-6951-6855
  • Manoukian, Siranoush
  • Peissel, Bernard|||0000-0001-9233-3571
  • Ripamonti, Carla Barbara|||0000-0002-2892-8164
  • Bonanni, Bernardo|||0000-0003-3589-2128
  • Viel, Alessandra|||0000-0003-2804-0840
  • Allavena, Anna
  • Bernard, Loris
  • Radice, Paolo|||0000-0001-6298-4111
  • Friedman, Eitan|||0000-0002-6745-1733
  • Kaufman, Bella
  • Laitman, Yael
  • Dubrovsky, Maya
  • Milgrom, Roni
  • Jakubowska, Anna|||0000-0002-5650-0501
  • Cybulski, Cezary|||0000-0002-2819-3057
  • Gorski, Bohdan
  • Jaworska, Katarzyna
  • Durda, Katarzyna
  • Sukiennicki, Grzegorz
  • Lubinski, Jan|||0000-0003-2931-3003
  • Shugart, Yin Yao
  • Domchek, Susan M.|||0000-0002-5914-7272
  • Letrero, Richard
  • Weber, Barbara L.
  • Hogervorst, Frans B. L.
  • Rookus, Matti A.
  • Collee, J. Magriet
  • Devilee, Peter|||0000-0002-8023-2009
  • Ligtenberg, Marjolijn J.
  • van der Luijt, Rob|||0000-0002-0018-1089
  • Aalfs, Cora M.
  • Waisfisz, Quinten|||0000-0002-7384-9182
  • Wijnen, Juul
  • van Roozendaal, Cornelis E. P.
  • HEBON, None
  • EMBRACE, None
  • Easton, Douglas F.|||0000-0003-2444-3247
  • Peock, Susan
  • Cook, Margaret
  • Oliver, Clare
  • Frost, Debra
  • Harrington, Patricia
  • Lalloo, Fiona
  • Eeles, Rosalind|||0000-0002-3698-6241
  • Izatt, Louise|||0000-0003-1258-4843
  • Chu, Carol
  • Eccles, Diana M.|||0000-0002-9935-3169
  • Douglas, Fiona
  • Brewer, Carole
  • Nevanlinna, Heli|||0000-0002-0916-2976
  • Heikkinen, Tuomas|||0000-0003-1154-6204
  • Couch, Fergus J.
  • Wang, Xianshu
  • Lindor, Noralane M.
  • Godwin, Andrew K.|||0000-0002-3987-9580
  • Caligo, Maria|||0000-0003-0589-1829
  • Lombardi, Grazia
  • Loman, Niklas
  • Karlsson, Per
  • Ehrencrona, Hans|||0000-0002-5589-3622
  • von Wachenfeldt, Anna
  • SWE-BRCA, None
  • Barkardottir, Rosa
  • Hamann, Ute|||0000-0001-6705-7624
  • Rashid, Muhammad U.|||0000-0002-7684-3122
  • Lasa, Adriana|||0000-0001-9957-9646
  • Caldes, Trinidad
  • Andrés Conejero, Raquel
  • Schmitt, Michael
  • Assmann, Volker
  • Stevens, Kristen
  • Offit, Kenneth
  • Curado, João
  • Tilgner, Hagen U.|||0000-0002-7058-3606
  • Guigó, Roderic|||0000-0002-5738-4477
  • Aiza, Gemma|||0000-0001-8654-3724
  • Brunet, Joan|||0000-0003-1945-3512
  • Castellsagué, Joan|||0000-0002-2579-3137
  • Martrat, Griselda
  • Urruticoechea, Ander|||0000-0003-0359-3641
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Tihomirova, L.
  • Goldgar, D. E.
  • Buys, S.
  • John, Esther M.
  • Miron, A.
  • Southey, M.
  • Daly, M.B.
  • BCFR, None
  • Schmutzler, R.K.
  • Wappenschmidt, B.
  • Meindl, A.
  • Arnold, N.
  • Deissler, H.
  • Varon-Mateeva, Raymonda
  • Sutter, C.
  • Niederacher, D.
  • Imyamitov, E.
  • Sinilnikova, O.M.
  • Stoppa-Lyonne, D.
  • Mazoyer, S.
  • Verny-Pierre, C.
  • Castera, L.
  • de Pauw, A.
  • Bignon, Y.J.
  • Uhrhammer, N.
  • Peyrat, J.P.
  • Vennin, P.
  • Ferrer, S.
  • Collonge-Rame, M.A.
  • Mortemousque, I.
  • GEMO Study Collaborators, None
  • Spurdle, A.B.
  • Beesley, J.
  • Chen, X.
  • Healey, S.
  • Barcellos-Hoff, M.H.
  • Gruber, S.B.
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Capella, Gabriel|||0000-0002-4669-7320
  • McGuffog, L.
  • Antoniou, A.C.
  • Chenevix-Trench, G.
  • Fleisch, M.C.
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Pujana, Miguel Angel|||0000-0003-3222-4044
Differentiated mammary epithelium shows apicobasal polarity, and loss of tissue organization is an early hallmark of breast carcinogenesis. In BRCA1 mutation carriers, accumulation of stem and progenitor cells in normal breast tissue and increased risk of developing tumors of basal-like type suggest that BRCA1 regulates stem/progenitor cell proliferation and differentiation. However, the function of BRCA1 in this process and its link to carcinogenesis remain unknown. Here we depict a molecular mechanism involving BRCA1 and RHAMM that regulates apicobasal polarity and, when perturbed, may increase risk of breast cancer. Starting from complementary genetic analyses across families and populations, we identified common genetic variation at the low-penetrance susceptibility HMMR locus (encoding for RHAMM) that modifies breast cancer risk among BRCA1, but probably not BRCA2, mutation carriers: n = 7,584, weighted hazard ratio (<inf.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Difficulties during delivery, brain ventricle enlargement and cognitive impairment in first episode psychosis

  • Verdolini, Norma|||0000-0001-9488-2881
  • Garcia Rizo, Clemente|||0000-0002-4855-1608
  • Mezquida, Gisela|||0000-0002-6080-2203
  • Janssen, Joost|||0000-0001-7613-2067
  • Corripio, Iluminada|||0000-0003-2562-711X
  • Bioque, Miquel|||0000-0001-6887-7149
  • Lobo, Antonio|||0000-0002-9098-655X
  • Vieta, Eduard|||0000-0002-0548-0053
  • Mané, Anna|||0000-0003-2127-349X
  • Roldan-Bejarano, Alexandra|||0000-0001-9905-3943
  • Cuesta, M.J.
  • Parellada, Mara|||0000-0001-7977-3601
  • Bernardo, Miquel|||0000-0001-8748-6717
  • Costas-Carrera, A.
  • Valli, Isabel|||0000-0003-3052-7383
  • Sánchez Torres, Ana Maria|||0000-0002-9505-2406
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Rapado-Castro, M.
  • de la Serna, Elena|||0000-0002-7869-9881
  • Crossley, N.
  • Penadés, R.
Background Patients with a first episode of psychosis (FEP) display clinical, cognitive, and structural brain abnormalities at illness onset. Ventricular enlargement has been identified in schizophrenia since the initial development of neuroimaging techniques. Obstetric abnormalities have been associated with an increased risk of developing psychosis but also with cognitive impairment and brain structure abnormalities. Difficulties during delivery are associated with a higher risk of birth asphyxia leading to brain structural abnormalities, such as ventriculomegaly, which has been related to cognitive disturbances. Methods We examined differences in ventricular size between 142 FEP patients and 123 healthy control participants using magnetic resonance imaging. Obstetric complications were evaluated using the Lewis-Murray scale. We examined the impact of obstetric difficulties during delivery on ventricle size as well as the possible relationship between ventricle size and cognitive impairment in both groups. Results FEP patients displayed significantly larger third ventricle size compared with healthy controls. Third ventricle enlargement was associated with diagnosis (higher volume in patients), with difficulties during delivery (higher volume in subjects with difficulties), and was highest in patients with difficulties during delivery. Verbal memory was significantly associated with third ventricle to brain ratio. Conclusions Our results suggest that difficulties during delivery might be significant contributors to the ventricular enlargement historically described in schizophrenia. Thus, obstetric complications may contribute to the development of psychosis through changes in brain architecture.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Suicidal ideation with and without intention to act, A transdiagnostic network analysis on the interplay between psychopathology, impulsivity, and childhood maltreatment

  • De Prisco, Michele|||0000-0002-2032-1181
  • Roberto Herrero, Natalia|||0000-0002-5391-2711
  • Andreo Jover, Jorge|||0000-0002-6703-8017
  • Ayad-Ahmed, Wala|||0000-0002-0786-0076
  • Bobes-Bascarán, Maria T.|||0000-0002-5279-504X
  • Canal-Rivero, Manuel|||0000-0002-5818-5103
  • Canosa García, Irene
  • Cebrià, Ana Isabel|||0000-0002-2632-8130
  • Crespo-Facorro, Benedicto|||0000-0003-0033-7132
  • Curto-Ramos, Javier
  • Díaz-Marsá, Marina|||0000-0003-1364-3163
  • Torre-Luque, Alejandro de la|||0000-0003-0595-6127
  • Elices, M.|||0000-0002-7034-4242
  • Jiménez-Treviño, Luis|||0000-0002-9551-8587
  • Palao Tarrero, Ángela|||0000-0003-2717-5807
  • Palao, Diego|||0000-0002-3323-6568
  • Pemau, Andrés|||0000-0002-5835-507X
  • Lopez-Pena, Maria Purificacion
  • Ruiz Veguilla, Miguel
  • Sáiz, Pilar A.|||0000-0002-5705-4523
  • Suárez-Soto, Elizabeth|||0000-0001-7599-0078
  • Courtet, Philippe|||0000-0002-6519-8586
  • Vieta, Eduard|||0000-0002-0548-0053
  • Grande, Iria|||0000-0002-0137-0666
  • Pérez Solà, Víctor|||0000-0002-5825-2337
Suicide represents a significant public health concern. Suicide prevention strategies are shifting toward transdiagnostic perspectives examining interrelated risk factors, but their interrelationships remain unclear. This study investigated relationships between psychopathological dimensions, impulsivity, and childhood maltreatment in individuals with suicidal ideation (SI), comparing those with versus without intention to act using network analysis. Data were obtained from the Suicide Prevention and Intervention Study project. Participants were categorized into two groups based on their intention to act according to the Columbia Suicide Severity Rating Scale. Psychological symptoms, impulsivity traits, and childhood maltreatment were assessed. Network analysis was performed, and centrality measures were computed. A total of 1,265 individuals were categorized into the SI without intention to act (n = 345) and SI with intention to act (n = 920) groups. The former showed lower depression and hostility scores, and lower prevalence of major depressive and anxiety disorders. Network analyses revealed that in the SI without intention to act group, obsessive-compulsive symptoms were central, connecting to depression and anxiety, while negatively correlating with non-planning impulsivity. In contrast, the SI with intention to act group showed a more densely interconnected network where emotional abuse served as a bridge between childhood maltreatment and other psychopathological dimensions. This study identifies symptom interaction patterns between individuals with SI without and with intention to act. Understanding these relationships may improve suicide risk assessment and inform personalized interventions, potentially reducing the transition from ideation to action. Trauma-focused approaches addressing emotional abuse may be especially relevant for individuals at high risk.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fine-mapping genomic loci refines bipolar disorder risk genes

  • Koromina, Maria|||0000-0001-8843-082X
  • Ravi, Ashvin
  • Panagiotaropoulou, Georgia
  • Schilder, Brian M.|||0000-0001-5949-2191
  • Humphrey, Jack
  • Braun, Alice|||0000-0003-1145-0261
  • Bigdeli, Tim B.|||0000-0003-2215-5946
  • Chatzinakos, Chris
  • Coombes, Brandon J.|||0000-0003-4322-5923
  • Kim, Jaeyoung|||0000-0001-6983-7907
  • Liu, Xiaoxi|||0000-0002-1933-8613
  • Terao, Chikashi|||0000-0002-6452-4095
  • O'Connell, Kevin S.|||0000-0002-6865-8795
  • Adams, Mark J
  • Adolfsson, Rolf
  • Alda, Martin|||0000-0001-9544-3944
  • Alfredsson, Lars|||0000-0003-1688-6697
  • Andlauer, Till F. M.|||0000-0002-2917-5889
  • Andreassen, Ole A.|||0000-0002-4461-3568
  • Antoniou, Anastasia
  • Baune, Bernhard T.|||0000-0001-6548-426X
  • Bengesser, Susanne
  • Biernacka, Joanna
  • Boehnke, Michael|||0000-0002-6442-7754
  • Bosch, Rosa|||0000-0002-7596-183X
  • Cairns, Murray J.
  • Carr, Vaughan J.
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Catts, Stanley
  • Cichon, Sven|||0000-0002-9475-086X
  • Corvin, Aiden
  • Craddock, Nicholas
  • Dafnas, Konstantinos
  • Dalkner, Nina
  • Dannlowski, Udo|||0000-0002-0623-3759
  • Degenhardt, Franziska
  • Di Florio, Arianna
  • Dikeos, Dimitris
  • Fellendorf, Frederike Tabea
  • Ferentinos, Panagiotis|||0000-0001-8531-5623
  • Forstner, Andreas J.
  • Forty, Liz|||0000-0002-4349-8414
  • Frye, Mark
  • Fullerton, Janice M.|||0000-0003-4014-4490
  • Gawlik, Micha
  • Gizer, Ian R.
  • Gordon-Smith, Katherine
  • Green, Melissa J.
  • Grigoroiu-Serbanescu, Maria
  • Guzman-Parra, Jose|||0000-0002-1463-6435
  • Hahn, Tim|||0000-0002-8929-4134
  • Henskens, Frans
  • Hillert, Jan|||0000-0002-7386-6732
  • Jablensky, Assen V.
  • Jones, Lisa|||0000-0002-5122-8334
  • Jones, Ian
  • Jonsson, Lina
  • Kelsoe, John R.
  • Kircher, Tilo|||0000-0002-2514-2625
  • Kirov, George|||0000-0002-3427-3950
  • Kittel-Schneider, Sarah|||0000-0003-3057-6150
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Landén, Mikael|||0000-0002-4496-6451
  • Leboyer, Marion|||0000-0001-5473-3697
  • Lenger, Melanie
  • Lissowska, Jolanta
  • Lochner, Christine|||0000-0002-4766-3704
  • Loughland, Carmel
  • MacIntyre, Donald J.|||0000-0001-6963-1335
  • Martin, Nicholas G.|||0000-0003-4069-8020
  • Maratou, Eirini
  • Mathews, Carol A.|||0000-0003-2208-7058
  • Mayoral-Cleries, Fermín
  • McElroy, Susan L.
  • McGregor, Nathaniel|||0000-0001-7195-4993
  • McIntosh, Andrew M.|||0000-0002-0198-4588
  • McQuillin, Andrew|||0000-0003-1567-2240
  • Michie, Patricia|||0000-0002-4169-8519
  • Mitchell, Philip B.
  • Moutsatsou, Paraskevi
  • Mowry, Bryan J.|||0000-0002-4115-5645
  • Müller-Myhsok, Bertram
  • Myers, Richard M.
  • Nenadić, Igor|||0000-0002-0749-7473
  • Nievergelt, Caroline M.
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Nurnberger, John
  • O'Donovan, Michael C.|||0000-0001-7073-2379
  • 'Donovan, Claire O.
  • Ophoff, Roel A.
  • Owen, Michael J.
  • Pantelis, Christos|||0000-0002-9565-0238
  • Pato, Carlos|||0000-0002-5858-266X
  • Pato, Michele T.
  • Patrinos, George P.
  • Pawlak, Joanna M.
  • Perlis, Roy H.|||0000-0002-5862-6757
  • Porichi, Evgenia
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Reif, Andreas|||0000-0002-0992-634X
  • Reininghaus, Eva Z.
  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Rietschel, Marcella|||0000-0002-5236-6149
  • Schall, Ulrich
  • Schofield, Peter R.|||0000-0003-2967-9662
  • Schulze, Thomas G.
  • Scott, Laura J.|||0000-0002-4886-5084
  • Scott, Rodney J.|||0000-0001-7724-3404
  • Serretti, Alessandro
  • Smoller, Jordan W.|||0000-0002-0381-6334
  • Świątkowska, Beata
  • Soler Artigas, María|||0000-0002-3213-1107
  • Stein, Dan J.|||0000-0001-7218-7810
  • Streit, Fabian|||0000-0003-1080-4339
  • Toma, Claudio|||0000-0003-3901-7507
  • Tooney, Paul
  • Vawter, Marquis P.
  • Vieta, Eduard|||0000-0002-0548-0053
  • Vincent, John B.
  • Waldman, Irwin D.|||0000-0002-6862-1837
  • Weickert, Cynthia Shannon
  • Weickert, Thomas
  • Witt, Stephanie H.|||0000-0002-1571-1468
  • Hong, Kyung Sue
  • Ikeda, Masashi|||0000-0001-6237-2449
  • Iwata, Nakao|||0000-0003-3189-6076
  • Won, Hong Hee
  • Edenberg, Howard J.|||0000-0003-0344-9690
  • Ripke, Stephan|||0000-0003-3622-835X
  • Raj, Towfique|||0000-0002-9355-5704
  • Coleman, Jonathan R.I.
  • Mullins, Niamh
Bipolar disorder is a heritable mental illness with complex etiology. While the largest published genome-wide association study identified 64 bipolar disorder risk loci, the causal SNPs and genes within these loci remain unknown. We applied a suite of statistical and functional fine-mapping methods to these loci and prioritized 17 likely causal SNPs for bipolar disorder. We mapped these SNPs to genes and investigated their likely functional consequences by integrating variant annotations, brain cell-type epigenomic annotations, brain quantitative trait loci and results from rare variant exome sequencing in bipolar disorder. Convergent lines of evidence supported the roles of genes involved in neurotransmission and neurodevelopment, including SCN2A, TRANK1, DCLK3, INSYN2B, SYNE1, THSD7A, CACNA1B, TUBBP5, FKBP2, RASGRP1, FURIN, FES, MED24 and THRA among others in bipolar disorder. These represent promising candidates for functional experiments to understand biological mechanisms and therapeutic potential. Additionally, we demonstrated that fine-mapping effect sizes can improve performance of bipolar disorder polygenic risk scores across diverse populations and present a high-throughput fine-mapping pipeline.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A molecular convergence in the triad of parkinson's disease, depressive disorder and gut health is revealed by the inflammation-miRNA axis

  • Miquel-Rio, Lluís|||0000-0002-3547-6004
  • Jericó-Escolar, Judith
  • Yanes-Castilla, Claudia
  • Sarriés-Serrano, Unai
  • Paz, Verónica
  • Callado, Luis F.|||0000-0001-9941-012X
  • Meana, J. Javier|||0000-0002-7913-6714
  • Bortolozzi, Analía|||0000-0002-2069-9192
Parkinson's disease (PD) is a multisystem disorder frequently comorbid with non-motor symptoms like depressive disorder (DD) and gastrointestinal (GI) dysfunction. Chronic neuroinflammation and disruption of the gut-brain axis are implicated as shared pathological drivers, but the precise molecular mechanisms connecting these conditions remain elusive. We hypothesized that a common microRNA (miRNA)-mediated inflammatory profile underlies this clinical triad, representing a point of pathological convergence. We analyzed the expression of a panel of inflammatory bowel disease (IBD)-associated miRNAs, key inflammatory markers, and glial response in postmortem brain tissue (dorsolateral prefrontal cortex and caudate nucleus) from patients with PD, DD, and matched healthy controls. To investigate causality and gut-brain axis involvement, two mouse models were used: (i) PD-associated α-synucleinopathy was induced in dorsal raphe serotonin (5-HT) neurons; and (ii) DD-like based on corticosterone (CORT)-induced stress. Mice were assessed for depressive-like behaviors and GI dysmotility, and their brain (medial prefrontal cortex and caudate-putamen) and ileum tissues were analyzed for the same molecular markers. We identified a conserved miRNA pattern in the brains of both PD and DD patients, characterized by the significant downregulation of miR-199a-5p and miR-219a-5p and the upregulation of miR-200a-3p. This dysregulation was strongly associated with a pro-inflammatory state, as evidenced by increased expression of TNFα, IFN-γ, and NFκB1, as well as changes in the glial response. Mice with α-synucleinopathy in the 5-HT system exhibited a depression-like phenotype and reduced intestinal motility, accompanied by increased Iba1 and GFAP signal. Comparable effects were observed in mice subjected to CORT-induced stress. Notably, the same pattern of miRNAs and inflammatory cytokines observed in the human brain was replicated in the brain and ileum of DD-PD-like mice, providing direct evidence of a parallel pathological process spanning the gut-brain axis. This study identifies a specific inflammation-miRNA pathway as a common molecular mechanism connecting the pathophysiology of PD, DD, and gut dysfunction. This pattern represents a critical point of convergence that drives a shared, bidirectional inflammatory cascade along the gut-brain axis. Targeting this miRNA triad could provide a new therapeutic approach for addressing the motor, psychiatric, and GI symptoms of these interconnected disorders simultaneously.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Biocompatibility and internalization assessment of bare and functionalised mesoporous silica nanoparticles

  • Garrido-Cano, Iris
  • Herrera, Guadalupe
  • Cejalvo, Juan Miguel
  • Lluch, Ana
  • Eroles, Pilar
  • Candela-Noguera, Vicente
  • Marcos Martínez, María Dolores|||0000-0001-7079-8589
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] We report herein an evaluation of the effect of several mesoporous silica nanoparticles (MSNs) on the cellular uptake and in vitro cytotoxicity in human cells. Bare MSNs and MSNs functionalized with polyethylene glycol or hyaluronic acid are employed to evaluate uptake efficiency and mechanisms of endocytosis in cancer (MDA-MB-231) and non-cancer (MCF10A) cells. Moreover, changes in viability, cell cycle, oxidative stress, and mitochondrial membrane potential are evaluated. Our results confirm that MSNs are internalized efficiently by human cells and that uptake mechanisms differ for cell types and particles. We also confirm that MSNs are biocompatible materials that do not induce ROS/RNS production, nor changes on mitochondrial membrane potential or cell cycle., The authors want to thank the Spanish Government RTI2018-100910-B-C41 (MCUI/AEI/FEDER, UE) and PI18/01219 (ISCIII), the Generalitat Valenciana (PROMETEO/2018/024 and ACIF/2016/030), and CIBER-BBN (CB07/01/2012) and CIBER-ONC (CB16/12/00481) for support.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Metabolomic Biomarkers of Pulmonary Fibrosis in COVID-19 Patients One Year After Hospital Discharge

  • Botello-Marabotto, Marina Dolores
  • Tarraso, Julia
  • Mulet, Alba
  • Presa-Fernandez, Lucia
  • Fernandez-Fabrellas, Estrella
  • Rodriguez Portal, Jose A.
  • Ros, Jose A.
  • Lozano-Vicente, Desire
  • Signes-Costa, Jaime
  • Bernardos Bau, Andrea|||0000-0002-3842-5771
  • Martínez-Bisbal, M.Carmen|||0000-0002-8526-4413
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Coronavirus disease 2019 (COVID-19) global pandemic has affected more than 600 million people up to date. The symptomatology and severity of COVID-19 are very broad, and there are still concerns about the long-term sequelae that it can have on discharged patients. The development of pulmonary fibrotic sequelae after this infection is especially worrying. Our aim was to determine if there was a metabolomic signature that could predict the development of pulmonary fibrotic sequelae. It is a multicenter prospective observation subcohort based on the COVID-FIBROTIC study. A metabolomic analysis was performed by nuclear magnetic resonance (NMR) on serum samples from patients admitted with bilateral COVID-19 pneumonia collected 2 months after hospital discharge. One year after admission, clinical, functional and radiological data were collected from these same patients. Finally, 109 patients (mean age 57.68 [DS14.03], 65.13% male) were available. Fibrotic sequelae 1 year after COVID-19 disease were found in 33% of them. Based on the NMR analysis of the serum samples, it was possible to distinguish with 80.82% of sensitivity, 72.22% of specificity and 0.83 of an area under the curve (AUC) value which patients would have radiological signs of pulmonary fibrotic pattern 1 year after sample collection. According to the metabolites participating in the discriminative model and the univariate statistics, glucose, valine, and fatty acids (& boxH;CH-CH2-CH & boxH;) were suggested as potential biomarkers of the development of pulmonary fibrotic sequelae after COVID-19., This work was supported by project PID2021-126304OB-C41 funded by MCIN/AEI/10.13039/501100011033/and by European Regional Development Fund - A way of doing Europe and Generalitat Valenciana (project CIPROM/2021/007) and CIBER (CB07/01/2012). There has also been the support of Institute of Health Carlos III (COV20/01209, Ministry of Science and Innovation of Spain) and grants from the Valencian Society of Pulmonology (FNCV Grant 2022 IP: Lucia Fernandez Presa; FNCV Grant Coordinated Research Project 2022 IP: Jaime Signes-Costa), U26 NMR: Biomedical Applications II platform from Nanbiosis (Research Infrastructures & Services of CIBER-BBN) and Marina Botello - Marabotto PhD grant (FPU 2020) from Spanish' government.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Tear metabolomics for the diagnosis of primary open-angle glaucoma

  • Botello-Marabotto, Marina Dolores
  • Pinazo-Duran, M. Dolores
  • Martínez-Bisbal, M.Carmen|||0000-0002-8526-4413
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Primary Open-Angle Glaucoma (POAG) is the most prevalent glaucoma type, and the leading cause of irreversible visual impairment and blindness worldwide. Identification of early POAG biomarkers is of enormous value, as there is not an effective treatment for the glaucomatous optic nerve degeneration (OND). In this pilot study, a metabolomic analysis, by using proton (1H) nuclear magnetic resonance (NMR) spectroscopy was conducted in tears, in order to determine the changes of specific metabolites in the initial glaucoma eyes and to discover potential diagnostic biomarkers. A classification model, based on the metabolomic fingerprint in tears was generated as a non-invasive tool to support the preclinical and clinical POAG diagnosis. 1H NMR spectra were acquired from 30 tear samples corresponding to the POAG group (n = 11) and the control group (n = 19). Data were analysed by multivariate statistics (partial least squares-discriminant analysis: PLS-DA) to determine a model capable of differentiating between groups. The whole data set was split into calibration (65%)/validation (35%), to test the performance and the ability for glaucoma discrimination. The calculated PLS-DA model showed an area under the curve (AUC) of 1, as well as a sensitivity of 100% and a specificity of 83.3% to distinguish POAG group versus control group tear data. This model included 11 metabolites, potential biomarkers of the disease. When comparing the study groups, a decrease in the tear concentration of phenylalanine, phenylacetate, leucine, n-acetylated compounds, formic acid, and uridine, was found in the POAG group. Moreover, an increase in the tear concentration of taurine, glycine, urea, glucose, and unsaturated fatty acids was observed in the POAG group. These results highlight the potential of tear metabolomics by 1H NMR spectroscopy as a non-invasive approach to support early POAG diagnosis and in order to prevent visual loss., This research was supported, in part by: 1) project PID2021- 126304OB-C41 funded by MCIN/AEI/10.13039/501100011033/and by European Regional Development Fund - A way of doing Europe, 2) Generalitat Valenciana (CIPROM/2021/007), 3) Universitat Politecnica de Valencia and FISABIO through the POLISABIO Research Program (PI2022_02), 4) General Sub-Directorate of Networks and Cooperative Research Centers of the Carlos III Health Institute, Spanish Ministry of Economy, Industry and Competitiveness, and by the European Program FEDER, to the Spanish Research Network of Prevention, Early Detection, Treatment and Rehabilitation of Ophthalmic Pathology (OFTARED: RD16/0008/002), 5) Spanish Ministry of Science and Innovation program Cooperative Research Networks Oriented to Health Results (RIC-ORS), to the Spanish Research Net of Inflammation and immunopathology of organs and systems REI RICORS, of the Carlos III Health Institute (RD21/0002/0032) and the European Program FEDER Next Generation EU. 6) CIBER -Consorcio Centro de Investigacion Bio-medica en Red- (CB07/01/2012), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion. U26 NMR: Biomedical Applications II platform from Nanbiosis (Research Infrastructures & Services of CIBER- BBN) is also gratefully acknowledged. Finally, M. Botello Marabotto acknowledges Spanish Government for her PhD grant (FPU20/05279).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Targeted detection of Mycobacterium tuberculosis MPT64 antigen using an antibody-coated nanoporous anodic alumina biosensor: A novel approach for tuberculosis screening

  • Caballos, Isabel
  • Climent Terol, Estela
  • Gil-Brusola, Ana
  • Hernández-Montoto, Andy|||0000-0001-5623-9836
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Aznar, Elena|||0000-0003-0361-3876
[EN] Tuberculosis (TB) is a chronic condition caused by Mycobacterium tuberculosis. According to WHO's Global Tuberculosis Report 2024, TB has again become the leading cause of death from a single infectious agent, surpassing COVID-19 in 2023 and 2024 in terms of infectious disease deaths. Due to its high infectivity and serious effects, timely diagnosis and treatment are crucial for controlling its spread. This study presents a fluorogenic biosensor for detecting M. tuberculosis MPT64 antigen using gated nanoporous anodic alumina (NAA). NAA material is loaded with rhodamine B and capped with an antibody against MPT64 protein. The presence of MPT64 induces antibody displacement due to the specific recognition and subsequent release of rhodamine B to the medium that is detected by fluorescence measurement. The biosensor is physicochemically characterized by scanning electron microscopy and X-ray spectroscopy. The biosensor achieves a limit of detection (LOD) of 1.32 nM (0.032 mg L-1) for MPT64 protein and demonstrated high selectivity through testing against various antigens from other viral pathogens and bacterial species. The efficacy of the biosensor is further validated with grown mycobacteria from clinical samples. The developed approach offers three key aspects: (i) selective detection of active TB by targeting the secreted MPT64 protein using gated nanomaterials; (ii) a rapid response (60 min); and (iii) a cost-effective design suitable for resource-limited settings. This biosensor shows great potential as a tool for the clinical diagnosis of active tuberculosis., We thank PID2024-155683OB-C41 and PID2021-126304OB-C41 from the Ministerio de Ciencia, Innovacion y Universidades and AEI/10.13039/501100011033 (co-financed by the European Regional Development Fund) , and CIPROM/2021/007 (to R. M.-M.) from the Generalitat Valenciana. This research was also supported by CIBER, Instituto de Salud Carlos III (group CB07/01/2012) . I.-C. thanks the Instituto de Salud Carlos III for her predoctoral fellowship (IFI21/00008) . We thank electron microscopy service of UPV for their support. R.M.M. thanks to the European Union's Horizon EUROPE research and innovation programme under grant agreement No 101093042. E. C. thanks the Instituto de Salud Carlos III for funding the proyects Miguel Servet 2023 CP23/00086 and PI24_01239, both co-funded by the European Union.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

A machine learning approach for type 2 diabetes diagnosis and prognosis using tailored heterogeneous feature subsets

  • Navarro Cerdan, José Ramón|||0000-0002-6692-5941
  • Arlandis, Joaquim|||0000-0003-2472-8883
  • Llobet Azpitarte, Rafael|||0000-0002-8278-9740
  • Perez-Cortes, Juan-Carlos|||0000-0001-6506-090X
  • Pons-Suñer, Pedro
  • Arnal, Laura
  • Lara-Hernández, Francisco
  • Moya-Valera, Celeste
  • Quiroz-Rodriguez, Maria Elena
  • Rojo-Martinez, Gemma
  • Valdés, Sergio
  • Montanya, Eduard
  • Calle-Pascual, Alfonso L.
  • Franch-Nadal, Josep
  • Delgado, Elias
  • Luis Castaño
  • Ana-Bárbara García-García
  • Chaves-Martinez, Felipe Javier
[EN] Type 2 diabetes (T2D) is becoming one of the leading health problems in Western societies, diminishing quality of life and consuming a significant share of healthcare resources. This study presents machine learning models for T2D diagnosis and prognosis, developed using heterogeneous data from a Spanish population dataset (Di@bet.es study). The models were trained exclusively on individuals classified as controls and undiagnosed diabetics, ensuring that the results are not influenced by treatment effects or behavioral changes due to disease awareness. Two data domains are considered: environmental (patient lifestyle questionnaires and measurements) and clinical (biochemical and anthropometric measurements). The preprocessing pipeline consists of four key steps: geospatial data extraction, feature engineering, missing data imputation, and quasiconstancy filtering. Two working scenarios (Environmental and Healthcare) are defined based on the features used, and applied to two targets (diagnosis and prognosis), resulting in four distinct models. The feature subsets that best predict the target have been identified based on permutation importance and sequential backward selection, reducing the number of features and, consequently, the cost of predictions. In the Environmental scenario, models achieved an AUROC of 0.86 for diagnosis and 0.82 for prognosis. The Healthcare scenario performed better, with an AUROC of 0.96 for diagnosis and 0.88 for prognosis. A partial dependence analysis of the most relevant features is also presented. An online demo page showcasing the Environmental and Healthcare T2D prognosis models is available upon request., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The activities described in this document are part of the Cervera Network of Excellence in Data-Based Enabling Technologies (AI4ES) project, which is co-financed by the Center for Industrial Technological Development, E.P.E. (CDTI) and by the European Union through the Next Generation EU Fund, within the Cervera aid program for Technology Centers by the CDTI, with file number CER-20211030. This research was also funded by Generalitat Valenciana through IVACE and the European Union through FEDER funds, PANAKEIA project IMDEEA/2023/92. This work was also funded by Generalitat Valenciana through IVACE through a grant to support ITI s activity in independent research and development, research results dissemination and knowledge and technology transfer to business under project IMAMCA/2023/11. Research grants PI17/00544 and PI21/00506 from Ministerio de Ciencia e Innovación and Instituto de Salud Carlos III (ISCIII). CIBERDEM (CB07/08/0018) is part of CIBER (Consorcio Centro de Investigación Biomédica en Red) funded by ISCIII. Both research projects and CIBER are co-funded by the European Union (European Regional Development Fund (ERDF) A way to build Europe ). Funding for open access charge: CRUE-Universitat Politècnica de València.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Impact of High-Intensity Interval Exercise With Elastic Bands Versus Continuous Moderate-Intensity Aerobic Exercise on Glycemic Control in People With Type 1 Diabetes

  • Martin-San Agustin, Rodrigo
  • Cuerda del Pino, Alba
  • Laguna Sanz, Alejandro José
  • Palanca, Ana
  • Rossetti, Paolo
  • Cynthia Marco Romero
  • Ampudia-Blasco, F. Javier
  • Bondía Company, Jorge|||0000-0001-7286-3719
[EN] Background: Engaging in physical exercise is recommended to enhance cardiovascular health and manage blood sugar levels in people with type 1 diabetes (T1D). Hypothesis: The impact of high-intensity interval exercise with elastic bands (EB-HIIE) versus continuous moderate-intensity aerobic exercise (CONT) on glycemic control is different in men with T1D. Study Design: Crossover study design. Level of Evidence: Level 3. Methods: Participants (39 men with T1D) underwent either an EB-HIIE or a CONT session in randomized order, with a separation of >= 72 hours to avoid carry-over effects. Changes in glucose values during exercise were measured simultaneously from venous blood (YSI) and interstitial fluid (Dexcom G6 glucose sensor). Subsequent 24-hour glucose was monitored using the glucose sensor. Results: Blood glucose was lower in CONT vs EB-HIIE (P < .01). Post hoc analysis revealed clinically relevant differences during exercise (-35.1 mg/dl; P = .02), at its end (-49.5 mg/dl; P < .01), and at 10 and 20 minutes after completion (-51.2 mg/dl; P < .01 and -45.9 mg/dl; P < .01, respectively). Time-in-range 24 hours after exercise completion was significantly higher with EB-HIIE than with CONT (66.5% vs 59.3%), although both were significantly better than the previous 24 hours before exercise (50%). Conclusion: Results suggest that EB-HIIE is a safe training method for male adults with diabetes, resulting in euglycemia during and immediately after exercise and improving glucose outcomes in the subsequent 24 hours. Clinical Relevance: This study provides new evidence and practical information on how to implement safe physical activity in daily life of patients with diabetes. EB-HIIT exhibited lower hypoglycemia risk during exercise and better glycemic control in the subsequent 24 hours. In contrast, practicing CONT exercise is associated with higher risk of hypoglycemia. Healthcare providers should take this information into account when prescribing exercise., The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grant PID2019- 107722RB-C21, funded by MCIN/AEI/10.13039/501100011033 and by CIBER-Consorcio Centro de Investigacion Biomedica en Red- group number CB17/08/00004 and CB07/08/0018, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion and by European Union-European Regional Development Fund. A.P. is a recipient of a Sara Borrell postdoctoral grant from the Instituto de Salud Carlos III (CD22/00012).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies

  • Garrido-Cano, Iris
  • Adam-Artigues, Anna
  • Lameirinhas, Ana
  • Blandez, Juan F.
  • Rojo, Federico
  • Zazo, Sandra
  • Madoz-Gúrpide, Juan
  • Lluch, Ana
  • Bermejo, Begoña
  • Cejalvo, Juan Miguel
  • Eroles, Pilar
  • Candela-Noguera, Vicente
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
This work was supported by Spanish Government and cofinanced by FEDER Funds (PI18/01219, PI21/01351, PI18/00382, and RTI2018-100910-B-C41), CIBERBBN (CB07/01/2012), CIBERONC (CB16/12/00481) and the Generalitat Valenciana (project PROMETEO 2018/024). I.G.-C. was funded by Generalitat Valenciana (ACIF/2016/030), A.A. and A.L. were funded by Asociación Española Contra el Cancer. J.F.B., was funded by Instituto de Salud Carlos III and the European Social Fund for the financial support Sara Borrell (CD19/00038), V.C.-N., was funded by Ministerio de Ciencia e Innovación (FPU grant), and J.M.C. was funded by Sociedad Española de Oncología Médica (Río Hortega-SEOM). We are especially grateful to the associations Amunt Contra el Cáncer, Asociación de la Lucha Contra el Cáncer de Montesa, and Corazón Solidario Contra el Cáncer. Funding for open access charge: Universitat Politècnica de València.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy

  • Garrido-Cano, Iris
  • Adam-Artigues, Anna
  • Lameirinhas, Ana
  • Blandez, Juan F.
  • Lluch, Ana
  • Bermejo, Begoña
  • Cejalvo, Juan Miguel
  • Eroles, Pilar
  • Candela-Noguera, Vicente
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Despite advancesin breast cancer treatment, it remainsthe leadingcause of cancer-related death in women worldwide. In this context,microRNAs have emerged as potential therapeutic targets but stillpresent some limitations for in vivo applications.Particularly, miR-200c-3p is a well-known tumor suppressor microRNAthat inhibits tumor progression and metastasis in breast cancer throughdownregulating ZEB1 and ZEB2. Basedon the above, we describe the design and validation of a nanodeviceusing mesoporous silica nanoparticles for miR-200c-3p delivery forbreast cancer treatment. We demonstrate the biocompatibility of thesynthesized nanodevices as well as their ability to escape from endosomes/lysosomesand inhibit tumorigenesis, invasion, migration, and proliferationof tumor cells in vitro. Moreover, tumor targetingand effective delivery of miR-200c-3p from the nanoparticles in vivo are confirmed in an orthotopic breast cancer mousemodel, and the therapeutic efficacy is also evidenced by a decreasein tumor size and lung metastasis, while showing no signs of toxicity.Overall, our results provide evidence that miR-200c-3p-loaded nanoparticlesare a potential strategy for breast cancer therapy and a safe andeffective system for tumor-targeted delivery of microRNAs., This research was supported by project PID2021-126304OB-C41 funded by MCIN/AEI/10.13039/501100011033/ and by European Regional Development Fund A way of doing Europe. Also, this study forms part of the Advanced Materials program (MFA/2022/049) and was supported by MCIN with funding from European Union NextGeneration EU(PRTR-C17.I1) and by Generalitat Valenciana. This study was also supported by Generalitat Valenciana (CIPROM/2021/007). This research was also supported by CIBER Consorcio Centro de Investigación Biomédica en Red CIBER-BBN(CB07/01/2012), CIBERONC(CB16/12/00481), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación. This work was also supported by Spanish Government and cofinanced by FEDER Funds (PI18/01219, PI21/01351) .I.G.-C. was funded by Margarita Salas post doctoral grant (European Union-Nextgeneration EU). A.A.-A. and A.L. were funded by Asociación Española Contra el Cancer.J.F.B. was funded by Instituto de Salud Carlos III and the European Social Fund for the financial support 'Sara Borrell' (CD19/00038). V.C.-N. was funded by Ministerio de Ciencia e Innovacio¿n (FPU grant), and J.M.C. was funded by Sociedad Española de Oncología Médica (Río Hortega-SEOM)
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Systematic study of the implications of calcination and solvent extraction of the surfactant in MCM-41-type mesoporous silica nanoparticles

  • Candela-Noguera, Vicente
  • Aznar, Elena|||0000-0003-0361-3876
  • Marcos Martínez, María Dolores|||0000-0001-7079-8589
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Amorós, Pedro
[EN] Mesoporous silica nanoparticles (MSN) have been growing in recent years in a broad range of applications, such as nanomedicine, catalysis, and gas storage. For the preparation of MSN, especially in nanomedicine applications, the extraction of the surfactant template, generally 1-hexadecyltrimethylammonium bromide (CTAB), is required. Several methods to remove the surfactant from MNS have been reported in the literature, such as calcination, solvent extraction, and dialysis. Depending on the method employed, the materials obtained have different properties; however, a systematic study that compares the use of different surfactant extraction methods and their implications in the final characteristics of the MSN has not been reported. Hence, the aim of this work is to study the effect of surfactant removal on MSN by calcination at different temperatures (400 degrees C, 450 degrees C, 500 degrees C and 550 degrees C) or by extraction with HCl/ethanol or NH 4 NO 3 /ethanol. The final materials are fully characterised by different techniques. The study performed shows the removal efficiency when the different methods are used, and their effect on silica condensation degree, mesoporosity, cytotoxicity, and degradation rate. The results allow for obtaining a deeper knowledge of the surfactant removal processes., V.C.-N. thanks the Spanish Government for his fellowship (FPU15/02753) . This research was supported by projects PID2021-126304OB-C41, PID2021-126304OB-C43 and PID2021-128141OB-C22 funded by MCIN/AEI/10.13039/501100011033/and by European Regional Development Fund-Away of doing Europe. This study also forms part of the Advanced Materials programme (MFA/2022/049 and MFA/2022/053) and was supported by MCIN with funding from European Union NextGenerationEU (PRTR-C17.I1) and by Generalitat Valenciana. This study was also supported by Generalitat Valenciana (CIPROM/2021/007) . This research was also supported by CIBER-Consorcio Centro de Investigacion Biomedica en Red- (CB07/01/2012) , Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion. The authors also thank the Electron Microscopy Service at UPV and SCSIE at UV for support. NMR was registered at the U26 facility of ICTS "NANBIOSIS" at the Universitat of Valencia.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Tesis doctoral (DoctoralThesis)

Role of miR-99a-5p in breast cancer: Translating molecular findings into clinical tools

  • Garrido Cano, Iris
[ES] La presente tesis doctoral, titulada "papel del miR-99a-5p en cáncer de mama: transformando hallazgos moleculares en herramientas clínicas" está centrada en el estudio del microRNA miR-99a-5p en cáncer de mama y en la determinación de su potencial como diana terapéutica y biomarcador para el diagnóstico de dicha enfermedad. En el primer capítulo, se lleva a cabo una revisión general del cáncer de mama y los microRNAs. A continuación, en el segundo capítulo se presentan los objetivos. En el tercer capítulo se compararon los perfiles de expresión de microRNAs de una línea celular de cáncer de mama resistente a doxorrubicina frente a la línea celular parental, dando lugar a la identificación del microRNA miR-99a-5p como el más desregulado entre ambas. A continuación, se confirmó que el miR-99a-5p aumenta la sensibilidad a doxorrubicina mediante la inhibición directa de la expresión de COX-2, que conlleva la inhibición de la expresión de la proteína ABCG2, ampliamente descrita por su papel en resistencia a fármacos. En base a los resultados obtenidos, se diseñaron nanodispositivos basados en nanopartículas mesoporosas de sílice para la liberación de miR-99a-5p y doxorrubicina en los tumores. Se confirmó la eficacia de las nanopartículas para reducir el crecimiento tumoral así como los efectos adversos asociados a la doxorrubicina libre en un modelo ortotópico murino de cáncer de mama. En el cuarto capítulo, se evaluó el potencial del miR-99a-5p como biomarcador para el diagnóstico del cáncer de mama. Se determinó la expresión del microRNA en tumores primarios de cáncer de mama y en tejidos sanos. Los resultados mostraron que el miR-99a-5p se encuentra infraexpresado en los tejidos cancerosos. A continuación, con el objeto de determinar el potencial del miR-99a-5p como biomarcador mínimamente invasivo, se determinaron los niveles de expresión en plasma de pacientes de cáncer de mama y de donantes sanos. Se encontró que el miR-99a-5p se encuentra a mayor concentración en el plasma de pacientes con cáncer de mama. Estos resultados se validaron en una cohorte independiente. Mediante el análisis en base a curvas ROC se confirmó que el miR-99a-5p es útil como biomarcador no invasivo para el diagnóstico del cáncer de mama incluso en estadíos tempranos de la enfermedad. El quinto capítulo se centra el diseño y validación de un biosensor basado en soportes de alúmina mesoporosa para la detección del miR-99a-5p en plasma. Los poros de una placa de alúmina mesoporosa se cargaron con el fluoróforo rodamina B, y se utilizaron oligonucleótidos complementarios a la secuencia del miR-99a-5p como puertas moleculares capaces de retener los fluoróforos en el interior de los poros. En presencia del miR-99a-5p, se produce liberación de rodamina B, que es posteriormente detectada ópticamente. Se confirmó la especificidad del biosensor, así como su alta sensibilidad. Además, utilizando muestras de plasma de pacientes de cáncer de mama y controles sanos, se confirmó la eficiencia del dispositivo para detectar cáncer de mama incluso en estadíos tempranos. Por último, en los capítulos cinco y seis se presentan la discusión general y las conclusiones principales extraídas. En conclusión, esta tesis doctoral demuestra que el miR-99a-5p tiene potencial como diana terapéutica y biomarcador para el cáncer de mama, y podría ser útil para mejorar el pronóstico de los pacientes con dicha enfermedad. Se ha elucidado que uno de los mecanismos por los que el miR-99a-5p está involucrado en sensibilidad a doxorrubicina es mediante la regulación del eje COX-2/ABCG2. Además, las nanopartículas diseñadas para la administración combinada de miR-99a-5p y doxorrubicina se presentan como una herramienta con gran potencial para el tratamiento oncológico. Por último, aprovechando el potencial del miR-99a-5p como biomarcador diagnóstico, se ha desarrollado un sistema de detección que podría ser una herramienta útil para mejorar la detección temprana del cáncer de mama., [CA] La present tesis doctoral, titulada "paper del miR-99a-5p en càncer de mama: transformant descobriments moleculars en eines clíniques" està centrada en l'estudi del microRNA miR-99a-5p en càncer de mama i en la determinació del seu potencial com a diana terapèutica i biomarcador per al diagnòstic d'aquesta malaltia. En el primer capítol, es du a terme una revisió general del càncer de mama i els microRNAs. A continuació, en el segon capítol es presenten els objectius. En el tercer capítol es van comparar els perfils d'expressió de microRNAs d'una línia cel·lular de càncer de mama resistent a doxorrubicina amb la seua línia parental, donant lloc a la identificació del microRNA miR-99a-5p com el més desregulat entre ambdues. A continuació, es va confirmar que el miR-99a-5p augmenta la sensibilitat al fàrmac mijançant la inhibició directa de l'expressió de COX-2 de forma directa, que comporta la inhibició de l'expressió de la proteïna ABCG2 que està àmpliament descrita pel seu paper en resistència a fàrmacs. Basant-se en els resultats obtinguts, es van dissenyar nanodispositius basats en nanopartícules mesoporoses de sílice per a l'alliberament d'una combinació de miR-99a-5p i doxorrubicina en els tumors. L'eficacia dels sistemes per a reduir el creixement tumoral així com els efectes adversos associats a la doxorrubicina lliure es va confirmar en un model ortotòpic murí de càncer de mama. En el quart capítol, es va avaluar el potencial del miR-99a-5p com a biomarcador per al diagnòstic del càncer de mama. Es va determinar l'expressió del microRNA en tumors primaris de càncer de mama i en teixits sans. Els resultats van mostrar que el miR-99a-5p es troba infraexpressat en els teixits cancerosos. A continuació, amb l'objectiu de determinar el potencial del miR-99a-5p com a biomarcador mínimament invasiu, es van determinar els nivells d'expressió en plasma de pacients de càncer de mama i de donants sans. Es va trobar que el miR-99a-5p es troba a major concentració en el plasma de pacients amb càncer de mama. Aquestos resultats es van validar en una cohort independent. Per mitjà de l'anàlisi basant-se en corbes ROC es va confirmar que el miR-99a-5p és útil com a biomarcador no invasiu per al diagnòstic del càncer de mama inclús en estadis primerencs de la malaltia. El quint capítol es centra en el disseny i validació d'un biosensor basat en suports d'alúmina nanoporosa per la detecció del miR-99a-5p en plasma. Els porus d'una placa d'alúmina es van carregar amb l'indicador fluorescent rodamina B, i es van utilitzar oligonucleòtids complementaris a la seqüència del miR-99a-5p com a portes moleculars amb la capacitat de retindre els fluoròfors a l'interior dels porus. En presència del miR-99a-5p, es produeix l'alliberament de rodamina B, que serà posteriorment detectada òpticament. Es va confirmar l'especificitat del biosensor, així com la seua alta sensibilitat. A més, utilitzant mostres de plasma de pacients de càncer de mama i controls sans, es va confirmar l'eficiència del dispositiu per a detectar càncer de mama inclús en estadis primerencs. Finalment, en els capítols sis i set es presenten la discussió general i les conclusions principals. En conclusió, aquesta tesi doctoral demostra que el miR-99a-5p té potencial com a diana terapèutica i biomarcador per al càncer de mama, i podria ser útil per a millorar el pronòstic dels pacients amb dita malaltia. S'ha elucidat que un dels mecanismes pels quals el miR-99a-5p està involucrat en sensibilitat a doxorrubicina és per mitjà de la regulació de l'eix COX-2/ABCG2. A més, les nanopartícules dissenyades per a l'administració combinada de miR-99a-5p i doxorrubicina es presenta com una ferramenta amb gran potencial per al tractament oncològic. Finalment, aprofitant el potencial del miR-99a-5p com a biomarcador diagnòstic, s'ha desenvolupat un sistema de detecció que podria ser una ferramenta útil per a millorar la detecció primerenca del càncer de mama., [EN] This PhD thesis, entitled "Role of miR-99a-5p in breast cancer: translating molecular findings into clinical tools" is focused on the study of the microRNA miR-99a-5p in breast cancer and in determining its potential as a therapeutic target and biomarker for the diagnosis of this disease. In the first chapter, a general review of breast cancer is carried out and microRNAs are also introduced. Next, in the second chapter, the objectives are detailed. In the third chapter, the microRNA expression profile of a doxorubicin-resistant breast cancer cell line was compared with its parental cell line, leading to the identification of the microRNA miR-99a-5p as the most deregulated between the two of them. Subsequently, it was confirmed that miR-99a-5p increases drug sensitivity through directly targeting COX-2, which leads to the inhibition of the expression of the ABCG2 protein, widely described to be involved in drug resistance. Based on the obtained results, nanodevices based on mesoporous silica nanoparticles were designed for the combined release of miR-99a-5p and doxorubicin in tumors. The ability of the systems to specifically target the CD44 receptor, which is overexpressed in breast cancer tumors, as well as to release the cargo specifically after internalization, were tested in vitro. Furthermore, the efficacy of the nanoparticles to reduce tumor growth and the adverse effects associated with free doxorubicin was confirmed in a murine orthotopic model of breast cancer. In the fourth chapter, the potential of miR-99a-5p as a biomarker for the diagnosis of breast cancer was evaluated. First, microRNA expression was determined in primary breast cancer tumors and compared with healthy tissues. The results showed that miR-99a-5p is downregulated in breast cancer tissues. Next, to determine the potential of the microRNA as a minimally invasive biomarker, the expression levels of miR-99a-5p in plasma of breast cancer patients and healthy donors were determined. In this case, it was found that miR-99a-5p is at higher concentrations in the plasma of breast cancer patients. These results were validated in an independent cohort. Through the ROC curve analysis, it was confirmed that miR-99a-5p is useful as a non-invasive biomarker for the diagnosis of breast cancer even at early stages. The fifth chapter focus on the design and validation of a biosensor based on nanoporous alumina supports for the detection of miR-99a-5p in plasma. The pores of the alumina plate were loaded with the fluorescent indicator rhodamine B, and oligonucleotides with a sequence complementary to the miR-99a-5p were used as molecular gates able to maintain fluorophores inside the pores. In the presence of miR-99a-5p, the capping oligonucleotide is displaced, leading to the opening of the pores and the release of rhodamine B, which is subsequently optically detected. The specificity and high sensitivity of the biosensor were confirmed. Furthermore, the efficiency of the device to detect breast cancer even at early stages was confirmed using plasma samples from breast cancer patients and healthy controls. Finally, chapters five and six present the general discussion and conclusions. In conclusion, this PhD thesis demonstrates that miR-99a-5p is a molecule with potential as a therapeutic target and biomarker for breast cancer, and it could be useful to improve the prognosis of patients. It has been elucidated that one of the mechanisms by which miR-99a-5p is involved in doxorubicin sensitivity is through the regulation of the COX-2/ABCG2 axis. Furthermore, nanoparticles designed for the combined administration of miR-99a-5p and doxorubicin are presented as a tool with great potential for cancer treatment and could be useful for the administration of microRNAs as therapy. Finally, taking advantage of the potential of miR-99a-5p as a diagnostic biomarker, a detection system has been developed and could be a useful tool to improve early detection of breast cancer., This work was supported by, CIBERONC (CB16/12/00481), CIBER-BBN (CB07/01/2012), Spanish Government PI18/01219 (ISCIII), project RTI2018- 100910-B-C41 (MCUI/AEI/FEDER, UE) and the Generalitat Valenciana (PROMETEO/2018/024) for support. IG-C was funded by Generalitat Valenciana (ACIF/2016/030). LP was funded by Ministerio de Economia, Industria y Competitividad (FPI grant). SS was funded by Instituto de Salud Carlos III and the European Social Fund for the financial support “Sara Borrell” (CD16/000237). JMC was funded by Sociedad Española de Oncología Médica (Río Hortega-SEOM. The authors would like to thank the INCLIVA Biobank (PT17/0015/0049; B.000768 ISCIII) and the Valencian Biobanking Network integrated into the Spanish National Biobanks Network for providing the human biological samples. We would also like to thank the plasma donors and the nursing staff that accepted to participate in this study.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Enzyme-Mediated Controlled Release Systems by Anchoring Peptide Sequences on Mesoporous Silica Supports

  • Coll Merino, Mª Carmen
  • Mondragón Martínez, Laura
  • Soto Camino, Juan
  • Amoros del Toro, Pedro Jose
  • Pérez Payá, Enrique
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Marcos Martínez, María Dolores|||0000-0001-7079-8589
[EN] Gated community: Peptides anchored to the surface of silica mesoporous supports by a valid procedure act as gatekeepers. In this way, "zero release" supports that selectively deliver the cargo in the presence of a suitable peptidase are obtained (see picture, red spheres: cargo, colored chains: peptides). © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim., We thank the Spanish Government (projects MAT2009-14564-C04, CB07/01/2012, and BIO2007 60066), the Generalitat Valencia (project PROMETEO/2009/016, PROMETEO/2010/005), and the CIBER-BBN for their support.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Impact of continuous moderate-intensity aerobic exercise on glycemic control according to different phases of the menstrual cycle in females with type 1 diabetes

  • Martín-San Agustín, Rodrigo
  • Cuerda del Pino, Alba
  • Laguna Sanz, Alejandro José
  • Rossetti, Paolo
  • Ampudia-Blasco, Francisco Javier
  • Bondía Company, Jorge|||0000-0001-7286-3719
[EN] Aim: To assess the effects of continuous moderate-intensity aerobic exercise (CONT) on glycemic control in women with type 1 diabetes (T1D) across different phases of the menstrual cycle. Methods: Twenty-five women with T1D completed two 30-minute CONT sessions: one during the follicular phase and the other during the luteal phase. Glycemic control was assessed during exercise by plasma glucose analysis and at 24 h post-exercise by continuous glucose monitoring. Results: A decline in blood glucose levels was observed after exercise, regardless of menstrual phase, from approximately 155 mg/dL to about 110 mg/dL. In the 24 h following exercise, the incidence of hypoglycemia was low (less than 2 %); in contrast, exercise in the luteal phase tended to increase hyperglycemia compared to the previous 24 h (from 38.2 % to 44.2 %), as well as compared to the follicular phase, with higher mean blood glucose levels observed. Conclusion: CONT has an immediate glucose-lowering effect regardless of menstrual cycle phase. However, while in the follicular phase TIR remains stable, in the luteal phase, it declines, with a corresponding increase in hyperglycemia, supporting the idea that exercise-induced glucose regulation varies across menstrual phases, highlighting the potential need for insulin dose adjustments depending on the cycle's phase., This work was supported by grant PID2019-107722RB-C21, funded by MCIN/AEI/10.13039/501100011033, as well as by CIBER-Consorcio Centro de Investigacion Biomedica en Red (Group Numbers CB17/08/00004 and CB07/08/0018), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion, and the European Union-European Regional Development Fund (ERDF) .
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Metabolomic study for the identification of symptomatic carotid plaque biomarkers

  • Botello-Marabotto, Marina Dolores
  • Plana Andani, Emma
  • Medina, Pilar
  • Miralles, Manuel
  • Martínez-Bisbal, M.Carmen|||0000-0002-8526-4413
  • Bernardos Bau, Andrea|||0000-0002-3842-5771
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Carotid artery stenosis is mainly produced due to the progressive accumulation of atherosclerotic plaque in the vascular wall. The atherosclerotic plaque is characterized by the accumulation of lipids, low density proteins, expression of chemokines and adhesion molecules, and migration of monocytes and lymphocytes into the plaque. Its rupture can produce stroke, but embolic propensity depends principally on the composition and vulnerability of plaque rather than the severity of stenosis. It is important, then, to ascertain which patients with carotid artery stenosis have a greater risk of developing neurological symptomatology. Here, we present a metabolomic study by using nuclear magnetic resonance (NMR) spectroscopy in atheroma plaque and serum samples from patients with recently symptomatic and asymptomatic carotid stenosis to search for metabolites that could be used as biomarkers associated with plaque vulnerability and subsequent risk of rupture. Thirty-eight atheromatous plaque samples (24 asymptomatic patients and 14 symptomatic) and 70 serum samples (43 asymptomatic and 27 symptomatic) were studied by NMR spectroscopy. The data were analysed using multivariate statistics (PLS-DA) to determine a model to discriminate between symptomatic and asymptomatic samples (atheroma plaques and sera). The calculated PLS-DA models showed a 100 % sensitivity and a 96.6 % specificity for the cross validation to discriminate between symptomatic and asymptomatic plaques, and 88.37% sensitivity and 77.78 % specificity when serum samples were analysed. According to the results of our multivariate and univariate analysis, the most discriminative metabolites for plaque vulnerability were threonine in serum samples, and glutamate in plaque samples. Also, an analysis of the main metabolic pathways involved in plaque vulnerability revealed that D-glutamine and D-glutamate metabolism, and phenylalanine, tyrosine, and tryptophan biosynthesis were the most affected pathways in plaque and serum, respectively., M. Botello-Marabotto acknowledges Generalitat Valenciana and the Spanish Government for her PhD grants ACIF/2020 and FPU 2020, respectively. Andrea Bernardos acknowledges her "Beatriz Galindo" contract from the MCIN (BG20/00020). This project has received the following funding: Instituto de Salud Carlos III (ISCIII) (PI20/01171 and PI20/00075) co-funded by the European Union (ERDF, "A way to make Europe") , project PID2021-126304OB-C41 and PID2021-128141OB-C22 funded by MCIN/AEI/10.13039/501100011033/and by European Regional Development Fund - A way of doing Europe and Generalitat Valenciana (project CIPROM/2021/007). La Fe Biobank (Hospital Universitario y Politecnico La Fe) is acknowledged for the storage and management of tissue samples (PT17/0015/0043). CIBER -Consorcio Centro de Investigacion Biomedica en Red- (CB07/01/2012), Ministerio de Ciencia e Innovacion and U26 NMR: Biomedical Applications II platform from Nanbiosis (Research Infrastructures & Services of CIBER-BBN) are also gratefully acknowledged.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Deep brain stimulation changes locus coeruleus responses to social stress from activation to inhibition

  • Torres-Sanchez, Sonia
  • Curtis, Andre L.
  • Valentino, Rita J.
  • Berrocoso Domínguez, Esther María
Deep Brain Stimulation (DBS) of the subgenual cingulate cortex (SCC) stands as an innovative therapeutic approach for treatment-resistant depression. Previous preclinical investigations utilizing DBS targeted at the ventromedial prefrontal cortex (vmPFC), considered the rodent equivalent of the human SCC, have demonstrated antidepressant-like effects, as well as enhancement in the activity of the locus coeruleus (LC)-norepinephrine (NE) system and pontine-cortical network oscillations. Given the association between social stress and depression and other psychiatric disorders, we assessed the impact of vmPFC DBS on social stress-induced changes in LC neuronal activity in awake rats. Spontaneous and auditory-evoked LC single unit activity were compared between control and DBS male rats during the first (acute) and fifth (repeated) day of social defeat stress. In stark contrast to LC activation observed in controls, both acute and repeated stress robustly inhibited LC neurons of DBS rats. While both groups experienced an acute stress-induced reduction in auditory-evoked LC discharge, the duration of the evoked response was only decreased in control animals. LC auditory-evoked activity was increased after repeated stress and DBS effectively counteracted these stress-induced alterations. These findings suggest that DBS treatment shifts stress-induced regulation of LC activity such that it favors the engagement of inhibitory modulation. This may serve to promote resistance of the LC-NE system to stress-induced excitation and contribute to the mitigation of neuropsychiatric consequences of stress.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Unraveling the potential of hypothalamic deep brain stimulation for obesity: Impacts on memory, neuroplasticity and brain metabolism in the Zucker rat

  • Casquero-Veiga, Marta
  • Llorca Torralba, Meritxell
  • Bueno-Fernandez, C.
  • Romero-Miguel, Diego
  • Lamanna-Rama, Nicolás
  • Winter, C.
  • Berrocoso Domínguez, Esther María
  • Nacher, Juan
  • Desco, Manuel
  • Soto-Montenegro, María Luisa
The lateral hypothalamus (LH) plays a key role in regulating energy balance and appetite, making it a potential target for deep brain stimulation (DBS) in treatment-resistant obesity. In this study, we evaluated the short and long-term in vivo effects of continuous LH-DBS over 15 days in a genetic model of obesity: the Zucker rat. We examined changes in body weight, brain glucose metabolism (via positron emission tomography, PET), and memory performance, along with ex vivo neuroplasticity in different hippocampal layers one month post-treatment. Contrary to expectations, continuous LH-DBS did not reduce the weight gain or food intake. While stimulated rats exhibited hippocampal hypermetabolism and enhanced synaptogenesis, these changes did not translate into cognitive improvements. Interestingly, long-term memory benefits were observed in all animals that underwent surgery, regardless of whether they received stimulation. In conclusion, our results do not support continuous LH-DBS as an effective treatment to reduce body weight in cases of obesity with genetic leptin resistance. However, the hippocampal modulation induced by continuous LH-DBS shows potential for addressing cognitive impairments associated with leptin resistance. These findings suggest that alternative DBS protocols may help restore hippocampal function, warranting further investigation.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

MicroRNA mapping of bronchial aspirate for molecular phenotyping and prognostication in patients on mechanical ventilation

  • Molinero, Marta
  • Benítez, Iván D.
  • Perez Pons, Manel
  • Rodríguez-Muñoz, Carlos
  • Gómez, Silvia
  • García Hidalgo, María C.
  • Sanchez-Rodriguez, Miguel
  • Gort-Paniello, Clara
  • Moncusí-Moix, Anna
  • Torres, Gerard
  • Ayestarán, Jose Ignacio
  • Socias, Lorenzo
  • Zuil, María
  • Motos, Ana
  • Fernández-Barat, Laia
  • Canseco, Joan
  • Recuerda Nuñez, María
  • Ortega, Alicia
  • Postigo, Tamara
  • Caballero, Jesús
  • Barberà, Carme
  • González, Jessica
  • Torres, Antoni
  • Barbé, Ferran
  • Bermejo Martin, Jesús F.
  • Estella García, Ángel
  • de Gonzalo-Calvo, David
The application of microRNA (miRNA) profiling in respiratory biospecimens, particularly bronchial aspirate (BAS), remains underexplored. Here, we aimed to validate and refine miRNA quantification in BAS samples to establish its suitability for molecular phenotyping. This was a multicenter study including 288 COVID-19 patients on invasive mechanical ventilation. Respiratory biospecimens included BAS, tracheal aspirate, and bronchoalveolar lavage fluid samples. A predesigned miRNA panel was evaluated using RT-qPCR. Biomarker evaluation and functional assessment were subsequently conducted. An initial technical validation phase corroborated the reproducibility of miRNA profiling in BAS samples. Comparative analyses of miRNA expression profiles across respiratory samples revealed distinct miRNA patterns among biospecimens. In the biomarker analysis, two miRNA ratios, miR-34c-5p/miR-34a-5p and miR-34c-5p/miR-125b-5p, were inversely associated with intensive care unit (ICU) survival (hazard ratio [HR]: 0.18 and 0.17, respectively) during the discovery phase. Risk and survival analyses in the test phase confirmed the reproducibility of the miR-34c-5p/miR-34a-5p ratio (hazard ratio [HR] = 0.17). Functional analyses revealed the utility of miRNA profiling in BAS for identifying pathogenic pathways and developing therapeutic targets. Overall, these findings position miRNA profiling in BAS samples as a valuable approach for biomarker discovery, iden tification of pathophysiological mechanisms, and development of targeted pulmonary therapies.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

MicroRNA mapping of bronchial aspirate for molecular phenotyping and prognostication in patients on mechanical ventilation

  • Molinero, Marta
  • Benítez, Iván
  • Perez Pons, Manel
  • Rodríguez Muñoz, Carlos
  • Gómez, Silvia
  • García Hidalgo, María
  • Sanchez Rodriguez, Miguel
  • Gort Paniello, Clara
  • Moncusí Moix, Anna
  • Torres Cortada, Gerard
  • Ayestarán, Jose Ignacio
  • Socias, Lorenzo
  • Zuil Moreno, María
  • Motos, Ana
  • Fernández Barat, Laia
  • Canseco, Joan
  • Nuñez, María Recuerda
  • Ortega, Alicia
  • Postigo, Tamara
  • Caballero, Jesús
  • Barberà, Carme
  • González, Jessica
  • Torres, Antoni
  • Barbé Illa, Ferran
  • Bermejo Martin, Jesús
  • Estella, Ángel
  • de Gonzalo Calvo, David
The application of microRNA (miRNA) profiling in respiratory biospecimens, particularly bronchial aspirate (BAS), remains underexplored. Here, we aimed to validate and refine miRNA quantification in BAS samples to establish its suitability for molecular phenotyping. This was a multicenter study including 288 COVID-19 patients on invasive mechanical ventilation. Respiratory biospecimens included BAS, tracheal aspirate, and bronchoalveolar lavage fluid samples. A predesigned miRNA panel was evaluated using RT-qPCR. Biomarker evaluation and functional assessment were subsequently conducted. An initial technical validation phase corroborated the reproducibility of miRNA profiling in BAS samples. Comparative analyses of miRNA expression profiles across respiratory samples revealed distinct miRNA patterns among biospecimens. In the biomarker analysis, two miRNA ratios, miR-34c-5p/miR-34a-5p and miR-34c-5p/miR-125b-5p, were inversely associated with intensive care unit (ICU) survival (hazard ratio [HR]: 0.18 and 0.17, respectively) during the discovery phase. Risk and survival analyses in the test phase confirmed the reproducibility of the miR-34c-5p/miR-34a-5p ratio (hazard ratio [HR] = 0.17). Functional analyses revealed the utility of miRNA profiling in BAS for identifying pathogenic pathways and developing therapeutic targets. Overall, these findings position miRNA profiling in BAS samples as a valuable approach for biomarker discovery, identification of pathophysiological mechanisms, and development of targeted pulmonary therapies., This work was supported by the Instituto de Salud Carlos III de Madrid (COV20/00110), cofunded by the European Union and Centro de Investigación Biomedica En Red—En fermedades Respiratorias (CIBERES). CIBERES (CB07/06/2008) is an initiative of the Instituto de Salud Carlos III. Further support was provided by the Programa de ciones “estar preparados” UNESPA (Madrid, Spain). F.B. is supported by the ICREA Academia Program. D.d.G.-C. has received financial support from Instituto de Salud Carlos III (Miguel Servet 2020: CP20/00041), cofunded by the European Union. M.M. (PFIS 2021: FI21/00187) and M.P.-P. (PFIS 2023: FI23/00022) are the recipients of a doctoral fellowship from Instituto de Salud Carlos III and cofunded by the European Union. MCGH held a predoctoral fellowship from Ayudas al Personal Investigador en Formación from IRBLleida/Diputación de Lleida. C.R. is supported by Departament de Salut (Pla Estratègic de Recerca i Innovació en Salut (PERIS): SLT028/23/000191) and programa predoctoral AGAUR-FI ajuts (2025 FI-2 00863) Joan Oró de la Secretaria d’Universitats i Recerca del Departament de Recerca i Universitats de la Generalitat de Catalunya i del Fons Europeu Social Plus. We want to particularly acknowledge the patients and the Biobanco A Coruña—Área Sanitaria A Coruña y Cee—SERGAS—INIBIC (B.0000796, PT17/0015/0032) and IdISBa Biobank and CIBERES Pulmonary Biobank Consortium (PT17/0015/0001), both integrated in the Spanish National Biobanks Network financed by the Carlos III Health Institute and the Units of Intensive Care, Clinical Analysis and Pulmonology of Hospital Universitario Son Espases, and Hospital Son Llatzer for their collaboration. This work was supported by the IRBLleida Biobank (B.000682) and the Biobank and Biomodels Platform ISCIII PT23/00032. Human sample manipulation was performed at the Cell Culture Facility, Universitat de Lleida (Lleida, Catalonia, Spain).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Adoptive NK cell transfer as a treatment in colorectal cancer patients: analyses of tumour cell determinants correlating with efficacy in vitro and in vivo

  • Lanuza, Pilar M.
  • Alonso, M. Henar
  • Hidalgo, Sandra
  • Uranga Murillo, Iratxe
  • García-Mulero, Sandra
  • Arnau, Raquel
  • Santos Vivas, Cristina
  • Sanjuan, Xavier
  • Santiago, Llipsy
  • Comas, Laura
  • Redrado, Sergio
  • Pazo-Cid, Roberto
  • Agustín Ferrández, M. J.
  • Jaime Sánchez, Paula
  • Pesini, Cecilia
  • Gálvez Buerba, Eva Mª
  • Ramírez-Labrada, Ariel
  • Arias, Maykel
  • Sanz-Pamplona, Rebeca
  • Pardo, Julián
6 figures., [Background]: Colorectal cancer (CRC) is a heterogeneous disease with variable mutational profile and tumour microenvironment composition that influence tumour progression and response to treatment. While chemoresistant and poorly immunogenic CRC remains a challenge, the development of new strategies guided by biomarkers could help stratify and treat patients. Allogeneic NK cell transfer emerges as an alternative against chemoresistant and poorly immunogenic CRC., [Methods]: NK cell-related immunological markers were analysed by transcriptomics and immunohistochemistry in human CRC samples and correlated with tumour progression and overall survival. The anti-tumour ability of expanded allogeneic NK cells using a protocol combining cytokines and feeder cells was analysed in vitro and in vivo and correlated with CRC mutational status and the expression of ligands for immune checkpoint (IC) receptors regulating NK cell activity., [Results]: HLA-I downmodulation and NK cell infiltration correlated with better overall survival in patients with a low-stage (II) microsatellite instability-high (MSI-H) CRC, suggesting a role of HLA-I as a prognosis biomarker and a potential benefit of NK cell immunotherapy. Activated allogeneic NK cells were able to eliminate CRC cultures without PD-1 and TIM-3 restriction but were affected by HLA-I expression. In vivo experiments confirmed the efficacy of the therapy against both HLA+ and HLA− CRC cell lines. Concomitant administration of pembrolizumab failed to improve tumour control., [Conclusions]: Our results reveal an immunological profile of CRC tumours in which immunogenicity (MSI-H) and immune evasion mechanisms (HLA downmodulation) favour NK cell immunosurveillance at early disease stages. Accordingly, we have shown that allogeneic NK cell therapy can target tumours expressing mutations conferring poor prognosis regardless of the expression of T cell-related inhibitory IC ligands. Overall, this study provides a rationale for a new potential basis for CRC stratification and NK cell-based therapy., Work in the JP laboratory is funded by ASPANOA, CIBER (CB 2021; Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación and Union Europea.NextGenerationEU), Fundacion Inocente, Carrera de la Mujer Monzón, FEDER/Gobierno de Aragón (Group B29_17R), and Ministerio de Ciencia, Innovación e Universidades (MCNU), Agencia Estatal de Investigación (SAF2017‐83120‐C2‐1‐R and PID2020-113963RB-I00). Predoctoral grants/contracts from Gobierno de Aragon (IU-M and JP) are supported by ARAID Foundation. EG is funded by Ministerio de Ciencia, Innovación y Universidades (MCNU), and Agencia Estatal de Investigación (PID2020-113963RB-I00). MA and LS are funded by Postdoctoral Juan de la Cierva Contract. SR, LC, SH, and IU-M are funded by predoctoral contracts from Aragon Government. PL is funded by FPU predoctoral grants from Ministerio de Ciencia, Innovación e Universidades. Work at the Catalan Institute of Oncology is funded by the entity, the Instituto de Salud Carlos III and Ministerio de Economia y Competitividad, and co-funded by FEDER funds—a way to build Europe (PI20/00767), CIBERESP (grant CB07/02/2005), H2020 grant MoTriColor, and the Agency for Management of University and Research Grants (AGAUR) of the Catalan Government grant 2017SGR723. This work is supported by COST Action CA17118., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Fine-mapping genomic loci refines bipolar disorder risk genes

  • Koromina, Maria
  • Ravi, Ashvin
  • Panagiotaropoulou, Georgia
  • Schilder, Brian M.
  • Humphrey, Jack
  • Braun, Alice
  • Bigdeli, Tim
  • Chatzinakos, Chris
  • Coombes, Brandon J.
  • Kim, Jaeyoung
  • Liu, Xiaoxi
  • Terao, Chikashi
  • O’Connell, Kevin S.
  • Adams, Mark J.
  • Adolfsson, Rolf
  • Alda, Martin
  • Alfredsson, Lars
  • Andlauer, Till F. M
  • Andreassen, Ole A.
  • Antoniou, Anastasia
  • Baune, Bernhard T.
  • Bengesser, Susanne
  • Biernacka, Joanna
  • Boehnke, Michael
  • Bosch, Rosa
  • Cairns, Murray J.
  • Carr, Vaughan J.
  • Casas, Miquel
  • Catts, Stanley
  • Cichon, Sven
  • Corvin, Aiden
  • Craddock, Nicholas
  • Dafnas, Konstantinos
  • Dalkner, Nina
  • Dannlowski, Udo
  • Degenhardt, Franziska
  • Di Florio, Arianna
  • Dikeos, Dimitris
  • Fellendorf, Frederike Tabea
  • Ferentinos, Panagiotis
  • Forstner, Andreas J.
  • Forty, Liz
  • Frye, Mark
  • Fullerton, Janice M.
  • Gawlik, Micha
  • Toma, Claudio
Statistical analyses were carried out on the NL Genetic Cluster Computer (http://www.geneticcluster.org) Nature Neuroscience Article https://doi.org/10.1038/s41593-025-01998-z hosted by SURFsara and the Mount Sinai high-performance computing cluster (http://hpc.mssm.edu), which is supported by the Office of Research Infrastructure of the National Institutes of Health (awards S10OD018522 and S10OD026880). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Full acknowledgements are included in the Supplementary Note. The list of grants supporting authors of the current work is as follows: Baszucki Brain Research Fund via the Milken Institute Center for Strategic Philanthropy (to N.M.); US National Institute of Mental Health (PGC4: R01MH124839 to N.M. and O.A.A.); Medical Research Foundation (grant MRF-001-0012-RG-COLE-C0930 to J.R.I.C.); NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London (to J.R.I.C.); Consorcio Centro de Investigación Biomédica en Red (CIBER; CB07/09/0004 to E.V.); Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (grants PI18/00805 and PI21/00787 (integrated into the Plan Nacional de I + D + I and cofinanced by ISCIII—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER)) to E.V.); Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021 SGR 01358 to E.V.); CERCA Programme (to E.V.); Department de Salut de la Generalitat de Catalunya for the PERIS (grant SLT006/17/00357 to E.V.); European Union Horizon 2020 research and innovation program—EU.3.1.1 (understanding health, wellbeing and disease—grant 754907 to E.V.) and EU.3.1.3 (treating and managing disease—grant 945151 to E.V.); CIBER (CB15/00154), Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation and grants PI18/01788 and PI22/00464: Integrated into the Plan Nacional de I + D + I and cofinanced by the ISCIII—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER; to J.A.R.Q.); Instituto de Salud Carlos III (to J.A.R.Q.); Instituto de Salud Carlos III and NEURON BIOPHARMA, S.A (grant JTC2021 to J.A.R.Q.); Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021 SGR 00840 to J.A.R.Q.); European Union Horizon 2020 research and innovation program (Eat2beNICE, grant 728018 and Timespan, grant 965381 to J.A.R.Q.); Australian National Health and Medical Research Council Investigator Grant (1177991 and 1176716 to P.B.M. and P.R.S., respectively); Japan Agency for Medical Research and Development (AMED; grants 22wm0425008, 21ek0109555, 21tm0424220, 21ck0106642, 23ek0410114 and 23tm0424225 to X.L.,C.T., M.I. and N.I.); Japan Society for the Promotion of Science (JSPS) KAKENHI (grants 21H02854 and JP20H00462 to X.L., C.T., M.I. and N.I.) and German Research Foundation (DFG; grants FOR2107 KI588/14-1, KI588/14-2, KI588/20-1 and KI588/22-1 to T.L.; DA1151/5-1, DA1151/5-2, DA1151/9-1, DA1151/10-1 and DA1151/11-1 to U.D.; SFB-TRR393 to T.L. and U.D.). We also gratefully acknowledge the investigators who comprise the PGC and note that biosamples and corresponding data were sampled, processed and stored in the Marburg Biobank CBBMR.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Arsenic exposure, diabetes-related genes and diabetes prevalence in a general population from Spain

  • Grau-Perez, M.
  • Navas-Acien, A.
  • Galan-Chilet, I.
  • Briongos-Figuero, L.S.
  • Morchon-Simon, D.
  • Bermudez, J.D.
  • Crainiceanu, C.M.
  • de Marco, G.
  • Rentero-Garrido, P.
  • Garcia-Barrera, T.
  • Gomez-Ariza, J.L.
  • Casasnovas, J.A.
  • Martin-Escudero, J.C.
  • Redon, J.
  • Chaves, F.J.
  • Tellez-Plaza, M.
Inorganic arsenic exposure may be associated with diabetes, but the evidence at low-moderate levels is not sufficient. Polymorphisms in diabetes-related genes have been involved in diabetes risk. We evaluated the association of inorganic arsenic exposure on diabetes in the Hortega Study, a representative sample of a general population from Valladolid, Spain. Total urine arsenic was measured in 1451 adults. Urine arsenic speciation was available in 295 randomly selected participants. To account for the confounding introduced by non-toxic seafood arsenicals, we designed a multiple imputation model to predict the missing arsenobetaine levels. The prevalence of diabetes was 8.3%. The geometric mean of total arsenic was 66.0 µg/g. The adjusted odds ratios (95% confidence interval) for diabetes comparing the highest with the lowest tertile of total arsenic were 1.76 (1.01, 3.09) and 2.14 (1.47, 3.11) before and after arsenobetaine adjustment, respectively. Polymorphisms in several genes including IL8RA, TXN, NR3C2, COX5A and GCLC showed suggestive differential associations of urine total arsenic with diabetes. The findings support the role of arsenic on diabetes and the importance of controlling for seafood arsenicals in populations with high seafood intake. Suggestive arsenic-gene interactions require confirmation in larger studies.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Psychometric properties of the engaged living scale (ELS) Spanish version in a large sample of Spanish pilgrims

  • Navarrete, J.
  • Colomer-Carbonell, A.
  • Sanabria-Mazo, J. P.
  • Luciano, J. V.
  • Soler, J.
  • García-Campayo, J.
  • Demarzo, M.
  • Montero-Marín, J.
  • Bohlmeijer, E. T.
  • Campos, D.
  • Cebolla, A.
  • Feliu-Soler, A.
Engaged Living (values clarity and committed action) is a main process of psychological flexibility as defined by Acceptance and Commitment Therapy. The Engaged Living Scale (ELS) was designed to measure it. The purpose of this study was to translate the ELS to Spanish and to examine the reliability and validity of its scores in a heterogeneous sample of 752 Spanish pilgrims of the Way of Saint James (pre-post analysis: n = 285). Confirmatory factor analyses were computed to study the structural validity of the ELS scores. In addition, network analyses were computed to examine convergent and discriminant validity. The included variables were engaged living, mindfulness facets, satisfaction with life, subjective happiness, affect, depression, anxiety, and perceived stress. Results showed that the Spanish version of the ELS is two-factorial (valued living [VL] and life fulfillment [LF]). The ELS scores showed good reliability. In addition, it was able to detect VL and LF changes after the Way underscoring its sensitivity to change. The network analyses indicated adequate convergent and discriminant validity of the ELS. Changes in satisfaction with life, life fulfillment, happiness, and valued living scores were most strongly associated with changes in perceived stress, affect, mindfulness facets, depression, and anxiety. In short, the Spanish version of the ELS appeared to be a reliable and valid instrument to assess the engaged response style in the current samples.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Lipin‐2 regulates the antiviral and anti‐inflammatory responses to interferon

  • de Pablo, Nagore
  • Meana, Clara
  • Martínez-García, Javier
  • Martínez-Vicente, Pablo
  • Albert, Manuel
  • Guerra, Susana
  • Angulo, Ana
  • Balsinde, Jesús
  • Balboa, María A
Abstract Interferons (IFN) are crucial antiviral and immunomodulatory cytokines that exert their function through the regulation of a myriad of genes, many of which are not yet characterized. Here, we reveal that lipin‐2, a phosphatidic acid phosphatase whose mutations produce an autoinflammatory syndrome known as Majeed syndrome in humans, is regulated by IFN in a STAT‐1‐dependent manner. Lipin‐2 inhibits viral replication both in vitro and in vivo. Moreover, lipin‐2 also acts as a regulator of inflammation in a viral context by reducing the signaling through TLR3 and the generation of ROS and release of mtDNA that ultimately activate the NLRP3 inflammasome. Inhibitors of mtDNA release from mitochondria restrict IL‐1β production in lipin‐2‐deficient animals in a model of viral infection. Finally, analyses of databases from COVID‐19 patients show that LPIN2 expression levels negatively correlate with the severity of the disease. Overall, these results uncover novel regulatory mechanisms of the IFN response driven by lipin‐2 and open new perspectives for the future management of patients with LPIN2 mutations.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

MicroRNA mapping of bronchial aspirate for molecular phenotyping and prognostication in patients on mechanical ventilation

  • Molinero, Marta
  • Benítez, Iván
  • Perez Pons, Manel
  • Rodríguez Muñoz, Carlos
  • Gómez, Silvia
  • García Hidalgo, María
  • Sanchez Rodriguez, Miguel
  • Gort Paniello, Clara
  • Moncusí Moix, Anna
  • Torres Cortada, Gerard
  • Ayestarán, Jose Ignacio
  • Socias, Lorenzo
  • Zuil Moreno, María
  • Motos, Ana
  • Fernández Barat, Laia
  • Canseco, Joan
  • Nuñez, María Recuerda
  • Ortega, Alicia
  • Postigo, Tamara
  • Caballero, Jesús
  • Barberà, Carme
  • González, Jessica
  • Torres, Antoni
  • Barbé Illa, Ferran
  • Bermejo Martin, Jesús
  • Estella, Ángel
  • de Gonzalo Calvo, David
The application of microRNA (miRNA) profiling in respiratory biospecimens, particularly bronchial aspirate (BAS), remains underexplored. Here, we aimed to validate and refine miRNA quantification in BAS samples to establish its suitability for molecular phenotyping. This was a multicenter study including 288 COVID-19 patients on invasive mechanical ventilation. Respiratory biospecimens included BAS, tracheal aspirate, and bronchoalveolar lavage fluid samples. A predesigned miRNA panel was evaluated using RT-qPCR. Biomarker evaluation and functional assessment were subsequently conducted. An initial technical validation phase corroborated the reproducibility of miRNA profiling in BAS samples. Comparative analyses of miRNA expression profiles across respiratory samples revealed distinct miRNA patterns among biospecimens. In the biomarker analysis, two miRNA ratios, miR-34c-5p/miR-34a-5p and miR-34c-5p/miR-125b-5p, were inversely associated with intensive care unit (ICU) survival (hazard ratio [HR]: 0.18 and 0.17, respectively) during the discovery phase. Risk and survival analyses in the test phase confirmed the reproducibility of the miR-34c-5p/miR-34a-5p ratio (hazard ratio [HR] = 0.17). Functional analyses revealed the utility of miRNA profiling in BAS for identifying pathogenic pathways and developing therapeutic targets. Overall, these findings position miRNA profiling in BAS samples as a valuable approach for biomarker discovery, identification of pathophysiological mechanisms, and development of targeted pulmonary therapies., This work was supported by the Instituto de Salud Carlos III de Madrid (COV20/00110), cofunded by the European Union and Centro de Investigación Biomedica En Red—En fermedades Respiratorias (CIBERES). CIBERES (CB07/06/2008) is an initiative of the Instituto de Salud Carlos III. Further support was provided by the Programa de ciones “estar preparados” UNESPA (Madrid, Spain). F.B. is supported by the ICREA Academia Program. D.d.G.-C. has received financial support from Instituto de Salud Carlos III (Miguel Servet 2020: CP20/00041), cofunded by the European Union. M.M. (PFIS 2021: FI21/00187) and M.P.-P. (PFIS 2023: FI23/00022) are the recipients of a doctoral fellowship from Instituto de Salud Carlos III and cofunded by the European Union. MCGH held a predoctoral fellowship from Ayudas al Personal Investigador en Formación from IRBLleida/Diputación de Lleida. C.R. is supported by Departament de Salut (Pla Estratègic de Recerca i Innovació en Salut (PERIS): SLT028/23/000191) and programa predoctoral AGAUR-FI ajuts (2025 FI-2 00863) Joan Oró de la Secretaria d’Universitats i Recerca del Departament de Recerca i Universitats de la Generalitat de Catalunya i del Fons Europeu Social Plus. We want to particularly acknowledge the patients and the Biobanco A Coruña—Área Sanitaria A Coruña y Cee—SERGAS—INIBIC (B.0000796, PT17/0015/0032) and IdISBa Biobank and CIBERES Pulmonary Biobank Consortium (PT17/0015/0001), both integrated in the Spanish National Biobanks Network financed by the Carlos III Health Institute and the Units of Intensive Care, Clinical Analysis and Pulmonology of Hospital Universitario Son Espases, and Hospital Son Llatzer for their collaboration. This work was supported by the IRBLleida Biobank (B.000682) and the Biobank and Biomodels Platform ISCIII PT23/00032. Human sample manipulation was performed at the Cell Culture Facility, Universitat de Lleida (Lleida, Catalonia, Spain).
Docta Complutense
Publicación Artículo científico (JournalArticle)

Maternal Diet Determines Milk Microbiome Composition and Offspring Gut Colonization in Wistar Rats

  • Martínez-Oca, Paula
  • Alba Rubio, Claudio
  • Sánchez Roncero, Alicia
  • Fernández-Marcelo, Tamara
  • Martín, María Ángeles
  • Escrivá Pons, Fernando
  • Rodríguez Gómez, Juan Miguel
  • Álvarez Escolá, Carmen
  • Fernández Millán, Elisa
Mother’s milk contains a unique microbiome that plays a relevant role in offspring health. We hypothesize that maternal malnutrition during lactation might impact the microbial composition of milk and affect adequate offspring gut colonization, increasing the risk for later onset diseases. Then, Wistar rats were fed ad libitum (Control, C) food restriction (Undernourished, U) during gestation and lactation. After birth, offspring feces and milk stomach content were collected at lactating day (L)4, L14 and L18. The V3–V4 region of the bacterial 16S rRNA gene was sequenced to characterize bacterial communities. An analysis of beta diversity revealed significant disparities in microbial composition between groups of diet at L4 and L18 in both milk, and fecal samples. In total, 24 phyla were identified in milk and 18 were identified in feces, with Firmicutes, Proteobacteria, Actinobacteroidota and Bacteroidota collectively representing 96.1% and 97.4% of those identified, respectively. A higher abundance of Pasteurellaceae and Porphyromonas at L4, and of Gemella and Enterococcus at L18 were registered in milk samples from the U group. Lactobacillus was also significantly more abundant in fecal samples of the U group at L4. These microbial changes compromised the number and variety of milk–feces or feces–feces bacterial correlations. Moreover, increased offspring gut permeability and an altered expression of goblet cell markers TFF3 and KLF3 were observed in U pups. Our results suggest that altered microbial communication between mother and offspring through breastfeeding may explain, in part, the detrimental consequences of maternal malnutrition on offspring programming.
Docta Complutense
Publicación Artículo científico (JournalArticle)

TSC2 N-terminal lysine acetylation status affects to its stability modulating mTORC1 signaling and autophagy

  • García Aguilar, Ana
  • Guillén
  • Guillén Viejo, Carlos
  • Nellist, Mark
  • Bartolomé, Alberto
  • Benito De Las Heras, Manuel R.
There is a growing evidence of the role of protein acetylation in different processes controlling metabolism. Sirtuins (histone deacetylases nicotinamide adenine dinucleotide-dependent) activate autophagy playing a protective role in cell homeostasis. This study analyzes tuberous sclerosis complex (TSC2) lysine acetylation, in the regulation of mTORC1 signaling activation, autophagy and cell proliferation. Nicotinamide 5mM (a concentration commonly used to inhibit SIRT1), increased TSC2 acetylation in its N-terminal domain, and concomitantly with an augment in its ubiquitination protein status, leading to mTORC1 activation and cell proliferation. In contrast, resveratrol (RESV), an activator of sirtuins deacetylation activity, avoided TSC2 acetylation, inhibiting mTORC1 signaling and promoting autophagy. Moreover, TSC2 in its deacetylated state was prevented from ubiquitination. Using MEF Sirt1 +/+ and Sirt1 -/- cells or a SIRT1 inhibitor (EX527) in MIN6 cells, TSC2 was hyperacetylated and neither NAM nor RESV were capable to modulate mTORC1 signaling. Then, silencing Tsc2 in MIN6 or in MEF Tsc2-/- cells, the effects of SIRT1 modulation by NAM or RESV on mTORC1 signaling were abolished. We also observed that two TSC2 lysine mutants in its N-terminal domain, derived from TSC patients, differentially modulate mTORC1 signaling. TSC2 K599M variant presented a lower mTORC1 activity. However, with K106Q mutant, there was an activation of mTORC1 signaling at the basal state as well as in response to NAM. This study provides, for the first time, a relationship between TSC2 lysine acetylation status and its stability, representing a novel mechanism for regulating mTORC1 pathway.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The role of distinctive sphingolipids in the inflammatory and apoptotic effects of electronegative LDL on monocytes

  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Estruch, Montserrat|||0000-0002-7162-4158
  • Jin, Lei
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Benitez, Sonia|||0000-0003-3565-0743
Electronegative low-density lipoprotein (LDL(-)) is a minor LDL subfraction that is present in blood with inflammatory and apoptotic effects. We aimed to evaluate the role of sphingolipids ceramide (Cer), sphingosine (Sph), and sphingosine-1-phosphate (S1P) in the LDL(-)-induced effect on monocytes. Total LDL was subfractioned into native LDL and LDL(-) by anion-exchange chromatography and their sphingolipid content evaluated by mass spectrometry. LDL subfractions were incubated with monocytes in the presence or absence of enzyme inhibitors: chlorpromazine (CPZ), D-erythro-2-(N-myristoyl amino)-1-phenyl-1-propanol (MAPP), and N,N-dimethylsphingosine (DMS), which inhibit Cer, Sph, and S1P generation, respectively. After incubation, we evaluated cytokine release by enzyme-linked immunosorbent assay (ELISA) and apoptosis by flow cytometry. LDL(-) had an increased content in Cer and Sph compared to LDL(+). LDL(-)-induced cytokine release from cultured monocytes was inhibited by CPZ and MAPP, whereas DMS had no effect. LDL(-) promoted monocyte apoptosis, which was inhibited by CPZ, but increased with the addition of DMS. LDL enriched with Sph increased cytokine release in monocytes, and when enriched with Cer, reproduced both the apoptotic and inflammatory effects of LDL(-). These observations indicate that Cer content contributes to the inflammatory and apoptotic effects of LDL(-) on monocytes, whereas Sph plays a more important role in LDL(-)-induced inflammation, and S1P counteracts apoptosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immunization with the Gly 1127 -Cys 1140 amino acid sequence of the LRP1 receptor reduces atherosclerosis in rabbits. Molecular, immunohistochemical and nuclear imaging studies

  • Bornachea, Olga
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Vea Badenes, Angela|||0000-0001-7856-6635
  • Nasarre, Laura
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Cedó, Lídia|||0000-0003-4354-3411
  • Iborra Obiols, Antoni|||0000-0002-8984-5151
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Juárez Rubio, Cándido|||0000-0003-2235-9893
  • Cámara, Juan Antonio|||0000-0001-7494-1127
  • Espinet, Carina|||0000-0001-8580-6617
  • Borrell-Pages, Maria|||0000-0002-1759-9756
  • Badimon, Lina|||0000-0002-9162-2459
  • Castell-Conesa, Joan|||0000-0002-6449-9731
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Background : The LRP1 (CR9) domain and, in particular, the sequence Gly 1127 -Cys 1140 (P3) plays a critical role in the binding and internalization of aggregated LDL (agLDL). We aimed to evaluate whether immunization with P3 reduces high-fat diet (HFD)-induced atherosclerosis. Methods : Female New Zealand White (NZW) rabbits were immunized with a primary injection and four reminder doses (R1-R4) of IrP (irrelevant peptide) or P3 conjugated to the carrier. IrP and P3-immunized rabbits were randomly divided into a normal diet group and a HFD-fed group. Anti-P3 antibody levels were determined by ELISA. Lipoprotein profile, circulating and tissue lipids, and vascular pro-inflammatory mediators were determined using standardized methods while atherosclerosis was determined by confocal microscopy studies and non-invasive imaging (PET/CT and Doppler ultrasonography). Studies treating human macrophages (hMΦ) and coronary vascular smooth muscle cells (hcVSMC) with rabbit serums were performed to ascertain the potential impact of anti-P3 Abs on the functionality of these crucial cells. Results : P3 immunization specifically induced the production of anti-P3 antibodies (Abs) and did not alter the lipoprotein profile. HFD strongly induced cholesteryl ester (CE) accumulation in the aorta of both the control and IrP groups, and their serum dose-dependently raised the intracellular CE of hMΦ and hcVSMC, promoting TNFR1 and phospho-NF-kB (p65) overexpression. These HFD pro-inflammatory effects were dramatically decreased in the aorta of P3-immunized rabbits and in hMΦ and hcVSMC exposed to the P3 rabbit serums. Microscopy studies revealed that P3 immunization reduced the percentage of lipids, macrophages, and SMCs in the arterial intima, as well as the atherosclerotic extent and lesion area in the aorta. PET/CT and Doppler ultrasonography studies showed that the average standardized uptake value (SUV) of the aorta and the arterial resistance index (ARI) of the carotids were more upregulated by HFD in the control and IrP groups than the P3 group. Conclusions : P3 immunization counteracts HFD-induced fatty streak formation in rabbits. The specific blockade of the LRP1 (CR9) domain with Anti-P3 Abs dramatically reduces HFD-induced intracellular CE loading and harmful coupling to pro-inflammatory signaling in the vasculature.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Electronegative LDL Promotes Inflammation and Triglyceride Accumulation in Macrophages

  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Montolio, Lara
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Navarra, Laia
  • Jiménez Altayó, Francesc|||0000-0002-9034-2041
  • Jiménez Xarrié, Elena|||0000-0003-3567-0672
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Benitez, Sonia|||0000-0003-3565-0743
Electronegative low-density lipoprotein (LDL) (LDL(-)), a modified LDL that is present in blood and exerts atherogenic effects on endothelial cells and monocytes. This study aimed to determine the action of LDL(-) on monocytes differentiated into macrophages. LDL(-) and in vitro-modified LDLs (oxidized, aggregated, and acetylated) were added to macrophages derived from THP1 monocytes over-expressing CD14 (THP1-CD14). Then, cytokine release, cell differentiation, lipid accumulation, and gene expression were measured by ELISA, flow cytometry, thin-layer chromatography, and real-time PCR, respectively. LDL(-) induced more cytokine release in THP1-CD14 macrophages than other modified LDLs. LDL(-) also promoted morphological changes ascribed to differentiated macrophages. The addition of high-density lipoprotein (HDL) and anti-TLR4 counteracted these effects. LDL(-) was highly internalized by macrophages, and it was the major inductor of intracellular lipid accumulation in triglyceride-enriched lipid droplets. In contrast to inflammation, the addition of anti-TLR4 had no effect on lipid accumulation, thus suggesting an uptake pathway alternative to TLR4. In this regard, LDL(-) upregulated the expression of the scavenger receptors CD36 and LOX-1, as well as several genes involved in triglyceride (TG) accumulation. The importance and novelty of the current study is that LDL(-), a physiologically modified LDL, exerted atherogenic effects in macrophages by promoting differentiation, inflammation, and triglyceride-enriched lipid droplets formation in THP1-CD14 macrophages, probably through different receptors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Particle size and cholesterol content of circulating HDL correlate with cardiovascular death in chronic heart failure

  • Teis, Albert|||0000-0002-4820-0736
  • Cediel, Germán|||0000-0001-9667-7507
  • Amigó, Núria|||0000-0002-0116-9145
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Aranyó, Júlia
  • Andrés-Cordón, Joan Francesc|||0000-0003-4264-4499
  • Puig Jové, Carlos|||0000-0001-9466-2627
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Gual-Capllonch, Francisco
  • Ferrer-Sistach, Elena|||0000-0002-1795-2193
  • Vallejo Camazón, Núria|||0000-0001-6644-6767
  • Juncà Puig, Gladys|||0000-0002-4421-5658
  • López Ayerbe, Jorge|||0009-0008-8495-0877
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Domingo, Mar|||0000-0002-2935-1272
  • Santiago Vacas, Evelyn|||0000-0001-7511-406X
  • Codina, Pau|||0000-0002-2469-5711
  • Mauricio, Didac|||0000-0002-2868-0250
  • Lupón, Josep|||0000-0002-5601-9611
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Evidence regarding any association of HDL-particle (HDL-P) derangements and HDL-cholesterol content with cardiovascular (CV) death in chronic heart failure (HF) is lacking. To investigate the prognostic value of HDL-P size (HDL-Sz) and the number of cholesterol molecules per HDL-P for CV death in HF patients. Outpatient chronic HF patients were enrolled. Baseline HDL-P number, subfractions and HDL-Sz were measured using 1H-NMR spectroscopy. The HDL-C/P ratio was calculated as HDL-cholesterol over HDL-P. Endpoint was CV death, with non-CV death as the competing event. 422 patients were included and followed-up during a median of 4.1 (0-8) years. CV death occurred in 120 (30.5%) patients. Mean HDL-Sz was higher in CV dead as compared with survivors (8.39 nm vs. 8.31 nm, p < 0.001). This change in size was due to a reduction in the percentage of small HDL-P (54.6% vs. 60% for CV-death vs. alive; p < 0.001). HDL-C/P ratio was higher in the CV-death group (51.0 vs. 48.3, p < 0.001). HDL-Sz and HDL-C/P ratio were significantly associated with CV death after multivariable regression analysis (HR 1.22 [95% CI 1.01-1.47], p = 0.041 and HR 1.04 [95% CI 1.01-1.07], p = 0.008 respectively). HDL-Sz and HDL-C/P ratio are independent predictors of CV death in chronic HF patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide -[113-122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice

  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Rull, Anna|||0000-0002-8907-7754
  • Aldana-Ramos, Joile
  • Santos, David|||0000-0003-1157-4969
  • Puig, Nuria
  • Farre-Cabrerizo, Nuria
  • Benitez, Sonia|||0000-0003-3565-0743
  • Pérez, Antonio|||0000-0001-5528-1143
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Ordóñez, J. (Jordi)|||0000-0003-4896-5832
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
Mimetic peptides are potential therapeutic agents for atherosclerosis. -[113-122]apolipoprotein (apo) J (-[113-122]apoJ) is a 10-residue peptide that is predicted to form a class G* amphipathic helix 6 from apoJ; it shows anti-inflammatory and anti-atherogenic properties. In the present study, we analyzed the effect of -[113-122]apoJ in low-density lipoprotein receptor knockout mice(LDLR-KO) on the development of atherosclerosis and lipoprotein function. Fifteen-week-old female LDLR-KO mice fed an atherogenic Western-type diet were treated for eight weeks with -[113-122]apoJ peptide, a scrambled peptide, or vehicle. Peptides were administered subcutaneously three days per week (200 µg in 100 µL of saline). After euthanasia, blood and hearts were collected and the aortic arch was analyzed for the presence of atherosclerotic lesions. Lipoproteins were isolated and their composition and functionality were studied. The extent of atherosclerotic lesions was 43% lower with -[113-122]apoJ treatment than with the vehicle or scramble. The lipid profile was similar between groups, but the high-density lipoprotein (HDL) of -[113-122]apoJ-treated mice had a higher antioxidant capacity and increased ability to promote cholesterol efflux than the control group. In addition, low-density lipoprotein (LDL) from -[113-122]apoJ-treated mice was more resistant to induced aggregation and presented lower electronegativity than in mice treated with -[113-122]apoJ. Our results demonstrate that the -[113-122]apoJ peptide prevents the extent of atherosclerotic lesions, which could be partially explained by the improvement of lipoprotein functionality.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma microRNA Profiling Reveals Novel Biomarkers of Epicardial Adipose Tissue, A Multidetector Computed Tomography Study

  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Viladés Medel, David|||0000-0002-3638-9703
  • Martínez-Camblor, Pablo|||0000-0001-7845-3905
  • Vea Badenes, Angela|||0000-0001-7856-6635
  • Ferrero-Gregori, Andreu|||0000-0001-6492-2416
  • Nasarre, Laura
  • Bornachea, Olga
  • Sánchez Vega, Jesús|||0000-0001-7250-8362
  • Leta, Rubén|||0000-0003-4691-381X
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Benitez, Sonia|||0000-0003-3565-0743
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Carreras Costa, Francesc|||0000-0002-1944-0562
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Epicardial adipose tissue (EAT) constitutes a novel parameter for cardiometabolic risk assessment and a target for therapy. Here, we evaluated for the first time the plasma microRNA (miRNA) profile as a source of biomarkers for epicardial fat volume (EFV). miRNAs were profiled in plasma samples from 180 patients whose EFV was quantified using multidetector computed tomography. In the screening study, 54 deregulated miRNAs were identified in patients with high EFV levels (highest tertile) compared with matched patients with low EFV levels (lowest tertile). After filtering, 12 miRNAs were selected for subsequent validation. In the validation study, miR-15b-3p, miR-22-3p, miR-148a-3p miR-148b-3p and miR-590-5p were directly associated with EFV, even after adjustment for confounding factors (p value < 0.05 for all models). The addition of miRNA combinations to a model based on clinical variables improved the discrimination (area under the receiver-operating-characteristic curve (AUC) from 0.721 to 0.787). miRNAs correctly reclassified a significant proportion of patients with an integrated discrimination improvement (IDI) index of 0.101 and a net reclassification improvement (NRI) index of 0.650. Decision tree models used miRNA combinations to improve their classification accuracy. These results were reproduced using two proposed clinical cutoffs for epicardial fat burden. Internal validation corroborated the robustness of the models. In conclusion, plasma miRNAs constitute novel biomarkers of epicardial fat burden.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Associations between epicardial adipose tissue, subclinical atherosclerosis and high-density lipoprotein composition in type 1 diabetes

  • Colom, Cristina|||0000-0002-2926-4697
  • Viladés Medel, David|||0000-0002-3638-9703
  • Pérez-Cuellar, Montserrat
  • Leta, Rubén|||0000-0003-4691-381X
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Carreras, Gemma|||0000-0002-6718-8381
  • Ordóñez, J. (Jordi)|||0000-0003-4896-5832
  • Pérez, Antonio|||0000-0001-5528-1143
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
The pathophysiology of cardiovascular complications in people with type 1 diabetes (T1DM) remains unclear. An increase in epicardial adipose tissue (EAT) and alterations in the composition of high-density lipoprotein (HDL) are associated with coronary artery disease, but information on its relationship in T1DM is very limited. Our aim was to determine the association between EAT volume, subclinical atherosclerosis, and HDL composition in type 1 diabetes. Seventy-two long-term patients with T1DM without clinical atherosclerosis were analyzed. EAT volume and subclinical atherosclerosis were measured using cardiac computed tomography angiography. EAT was adjusted according to body surface to obtain an EAT index (iEAT). HDL composition was determined. The mean iEAT was 40.47 ± 22.18 cc/m 2. The bivariate analysis showed positive associations of the iEAT with gender, age, hypertension, dyslipidemia, smoking, body mass index, waist circumference, insulin dose, and triglyceride (P < 0.05). The iEAT correlated positively with small HDL, increased content of apolipoprotein (apo)A-II and apoC-III, and decreased content of apoE and free cholesterol. Multiple linear regression showed that age, apoA-II content in HDL, and waist circumference were independently associated with the iEAT. Fifty percent of the patients presented subclinical atherosclerotic lesions. These patients had a higher iEAT, and their HDL contained less cholesterol and more apoA-II and lipoprotein-associated phospholipase A2 than patients without subclinical atherosclerosis. Alterations in the composition of HDL in TIDM are associated with increased iEAT and the presence of subclinical atherosclerosis. We propose that these abnormalities of HDL composition could be useful to identify T1DM patients at highest cardiovascular risk. The online version of this article (10.1186/s12933-018-0794-9) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

FGF-23/Vitamin D Axis in Type 1 Diabetes, The Potential Role of Mineral Metabolism in Arterial Stiffness

  • Llauradó, Gemma|||0000-0002-3237-6366
  • Megía, Ana|||0000-0002-5101-9452
  • Cano, Albert|||0000-0002-2804-3745
  • Giménez-Palop, Olga|||0000-0002-4526-6342
  • Simón, Inmaculada
  • González-Sastre, Montserrat
  • Berlanga Escalera, Eugenio|||0000-0002-9774-4051
  • Fernández-Veledo, Sonia|||0000-0003-2906-3788
  • Vendrell, Joan|||0000-0002-6994-6115
  • González Clemente, José Miguel|||0000-0002-7409-8720
To investigate the usefulness of Fibroblast Growth Factor 23 (FGF-23) and vitamin D as possible biomarkers of pre-clinical atherosclerosis, assessed as arterial stiffness (AS), in a group of subjects with type 1 diabetes (T1DM) and no previous cardiovascular events. 68 T1DM patients and 68 age- and sex-matched controls were evaluated for 1) age, sex, diabetes duration, physical activity, smoking, alcohol intake, BMI, blood pressure, fasting plasma glucose, HbA, estimated glomerular filtration rate (eGFR) and lipid profile; 2) microvascular complications; 3) blood concentrations of FGF-23 and mineral metabolism parameters (calcium, phosphate, parathyroid hormone (PTH) and 25-hydroxy-vitamin D (25(OH)D)); 4) AS, assessed as aortic pulse wave velocity (aPWV); and 5) low-grade inflammation (hsCRP, IL-6, sTNFαR1, sTNFαR2) and endothelial dysfunction (ED) markers (ICAM-1, VCAM-1, E-Selectin). Patients with T1DM had higher aPWV compared with controls (p<0.001), but they did not present differences in 25(OH)D (70.3(50.4-86.2)nmol/L vs. 70.7(59.7-83.0)nmol/L; p = 0.462) and in FGF-23 plasma concentrations (70.1(38.4-151.9)RU/mL vs. 77.6(51.8-113.9)RU/mL; p = 0.329). In T1DM patients, higher concentrations of FGF-23 were positively associated with aPWV after adjusting for eGFR and classical cardiovascular risk factors (model 1: ß = 0.202, p = 0.026), other mineral metabolism parameters (model 2: ß = 0.214, p = 0.015), microvascular complications, low-grade inflammation and ED markers (model 3: ß = 0.170, p = 0.045). Lower 25(OH)D concentrations were also associated with higher aPWV after adjusting for all the above-mentioned factors (model 3: ß = -0.241, p = 0.015). We conclude that both FGF-23 plasma concentrations (positively) and 25(OH)D serum concentrations (negatively) are associated with AS in patients with T1DM and no previous cardiovascular events.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Changes in the Composition and Function of Lipoproteins after Bariatric Surgery in Patients with Severe Obesity

  • Genua, Idoia|||0000-0001-6834-561X
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Miñambres, Inka|||0000-0002-0899-3938
  • Benitez, Sonia|||0000-0003-3565-0743
  • Gil, Pedro|||0000-0003-3707-7450
  • Grau-Agramunt, Margarida
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Balagué Ponz, Carmen|||0000-0003-2429-8297
  • Fernández-Alanin, Sonia
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Pérez, Antonio|||0000-0001-5528-1143
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
The effect of bariatric surgery on lipid profile and the qualitative characteristics of lipoproteins was analyzed in morbidly obese subjects. Thirteen obese patients underwent bariatric surgery. Plasma samples were obtained before surgery and at 6 and 12 months after the intervention. Thirteen healthy subjects comprised the control group. Lipid profile, hsCRP, and the composition and functional characteristics of VLDL, LDL, and HDL were assessed. At baseline, plasma from subjects with obesity had more triglycerides, VLDLc, and hsCRP, and less HDLc than the control group. These levels progressively normalized after surgery, although triglyceride and hsCRP levels remained higher than those in the controls. The main differences in lipoprotein composition between the obese subjects and the controls were increased apoE in VLDL, and decreased cholesterol and apoJ and increased apoC-III content in HDL. The pro-/anti-atherogenic properties of LDL and HDL were altered in the subjects with obesity at baseline compared with the controls, presenting smaller LDL particles that are more susceptible to modification and smaller HDL particles with decreased antioxidant capacity. Bariatric surgery normalized the composition of lipoproteins and improved the qualitative characteristics of LDL and HDL. In summary, patients with obesity present multiple alterations in the qualitative properties of lipoproteins compared with healthy subjects. Bariatric surgery reverted most of these alterations.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Cardiovascular Disease in Type 1 Diabetes Mellitus, Epidemiology and Management of Cardiovascular Risk

  • Colom, Cristina|||0000-0002-2926-4697
  • Rull, Anna|||0000-0002-8907-7754
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Pérez, Antonio|||0000-0001-5528-1143
Cardiovascular disease (CVD) is a major cause of mortality in type 1 diabetes mellitus (T1DM) patients, and cardiovascular risk (CVR) remains high even in T1DM patients with good metabolic control. The underlying mechanisms remain poorly understood and known risk factors seem to operate differently in T1DM and type 2 diabetes mellitus (T2DM) patients. However, evidence of cardiovascular risk assessment and management in T1DM patients often is extrapolated from studies on T2DM patients or the general population. In this review, we examine the existing literature about the prevalence of clinical and subclinical CVD, as well as current knowledge about potential risk factors involved in the development and progression of atherosclerosis in T1DM patients. We also discuss current approaches to the stratification and therapeutic management of CVR in T1DM patients. Chronic hyperglycemia plays an important role, but it is likely that other potential factors are involved in increased atherosclerosis and CVD in T1DM patients. Evidence on the estimation of 10-year and lifetime risk of CVD, as well as the efficiency and age at which current cardiovascular medications should be initiated in young T1DM patients, is very limited and clearly insufficient to establish evidence-based therapeutic approaches to CVD management.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Apolipoprotein and lrp1-based peptides as new therapeutic tools in atherosclerosis

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Solanelles Curco, Angels
  • García Rodríguez, Jesús Eduardo|||0000-0002-7758-6789
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Benitez, Sonia|||0000-0003-3565-0743
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Apolipoprotein (Apo)-based mimetic peptides have been shown to reduce atherosclerosis. Most of the ApoC-II and ApoE mimetics exert anti-atherosclerotic effects by improving lipid profile. ApoC-II mimetics reverse hypertriglyceridemia and ApoE-based peptides such as Ac-hE18A-NH2 reduce cholesterol and triglyceride (TG) levels in humans. Conversely, other classes of ApoE and ApoA-I mimetic peptides and, more recently, ApoJ and LRP1-based peptides, exhibit several antiatherosclerotic actions in experimental models without influencing lipoprotein profile. These other mimetic peptides display at least one atheroprotective mechanism such as providing LDL stability against mechanical modification or conferring protection against the action of lipolytic enzymes inducing LDL aggregation in the arterial intima. Other anti-atherosclerotic effects exerted by these peptides also include protection against foam cell formation and inflammation, and induction of reverse cholesterol transport. Although the underlying mechanisms of action are still poorly described, the recent findings suggest that these mimetics could confer atheroprotection by favorably influencing lipoprotein function rather than lipoprotein levels. Despite the promising results obtained with peptide mimetics, the assessment of their stability, atheroprotective efficacy and tissue targeted delivery are issues currently under progress.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Electronegative LDL Is Associated with Plaque Vulnerability in Patients with Ischemic Stroke and Carotid Atherosclerosis

  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Solé, Arnau|||0009-0007-6517-6188
  • Aguilera-Simón, Ana|||0000-0003-1428-8212
  • Jiménez Xarrié, Elena|||0000-0003-3567-0672
  • Fernández León, Alejandro|||0000-0002-1010-9451
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Guasch Jiménez, Marina|||0000-0001-6024-8348
  • Marín-Bueno, Rebeca|||0000-0002-0354-6602
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Martínez-Domeño, Alejandro|||0000-0002-9933-3192
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Casoni, Francesca
  • Pérez, Belén|||0000-0001-5801-1704
  • Jiménez Altayó, Francesc|||0000-0002-9034-2041
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Benitez, Sonia|||0000-0003-3565-0743
Owing to the high risk of recurrence, identifying indicators of carotid plaque vulnerability in atherothrombotic ischemic stroke is essential. In this study, we aimed to identify modified LDLs and antioxidant enzymes associated with plaque vulnerability in plasma from patients with a recent ischemic stroke and carotid atherosclerosis. Patients underwent an ultrasound, a CT-angiography, and an 18 F-FDG PET. A blood sample was obtained from patients (n = 64, 57.8% with stenosis ≥50%) and healthy controls (n = 24). Compared to the controls, patients showed lower levels of total cholesterol, LDL cholesterol, HDL cholesterol, apolipoprotein B (apoB), apoA-I, apoA-II, and apoE, and higher levels of apoJ. Patients showed lower platelet-activating factor acetylhydrolase (PAF-AH) and paraoxonase-1 (PON-1) enzymatic activities in HDL, and higher plasma levels of oxidized LDL (oxLDL) and electronegative LDL (LDL(-)). The only difference between patients with stenosis ≥50% and <50% was the proportion of LDL(-). In a multivariable logistic regression analysis, the levels of LDL(-), but not of oxLDL, were independently associated with the degree of carotid stenosis (OR: 5.40, CI: 1.15-25.44, p < 0.033), the presence of hypoechoic plaque (OR: 7.52, CI: 1.26-44.83, p < 0.027), and of diffuse neovessels (OR: 10.77, CI: 1.21-95.93, p < 0.033), indicating that an increased proportion of LDL(-) is associated with vulnerable atherosclerotic plaque.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus

  • Rodríguez-Calvo, Ricardo|||0000-0001-7513-0983
  • Granado-Casas, Minerva|||0000-0003-3447-5728
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Julián, María Teresa|||0000-0003-2524-1823
  • Domingo, Mar|||0000-0002-2935-1272
  • Codina, Pau|||0000-0002-2469-5711
  • Santiago Vacas, Evelyn|||0000-0001-7511-406X
  • Cediel, Germán|||0000-0001-9667-7507
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Rossell, Joana|||0000-0003-1500-6379
  • Masana, Luis|||0000-0002-0789-4954
  • Mauricio, Didac|||0000-0002-2868-0250
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
Subjects with type 2 diabetes mellitus (T2D) are at increased risk for heart failure (HF). The cardiac-specific (FABP3) and adipose-tissue-specific (FABP4) types of the fatty acid binding proteins have been associated with both all-cause and cardiovascular (CV) mortality. The aim of this study was to explore the prognosis value of FABP3 and FABP4 in ambulatory subjects with chronic HF (CHF), with and without T2D. A prospective study involving 240 ambulatory CHF subjects was performed. Patients were followed-up for a mean of 5.78 ± 3.30 years and cause of death (if any) was recorded. Primary endpoints were defined as all-cause and CV death, and a composite endpoint that included CV death or hospitalization for HF was included as a secondary endpoint. Baseline serum samples were obtained and the serum FABP3 and FABP4 concentrations were assessed by sandwich enzyme-linked immunosorbent assay. Survival analysis was performed with multivariable Cox regressions, using Fine and Gray competing risks models when needed, to explore the prognostic value of FABP3 and FABP4 concentrations, adjusting for potential confounders. Type 2 diabetes mellitus was highly prevalent, accounting for 47.5% for total subjects with CHF. Subjects with T2D showed higher mortality rates (T2D: 69.30%; non-T2D: 50.79%, p = 0.004) and higher serum FABP3 (1829.3 (1104.9-3440.5) pg/mL vs. 1396.05 (820.3-2362.16) pg/mL, p = 0.007) and FABP4 (45.5 (27.6-79.8) ng/mL vs. 34.1 (24.09-55.3) ng/mL, p = 0.006) concentrations compared with non-T2D CHF subjects. In the whole study cohort, FABP3 was independently associated with all-cause death, and both FABP3 and FABP4 concentrations were associated with CV mortality. The predictive values of these two molecules for all-cause (FABP3: HR 1.25, 95% CI 1.09-1.44; p = 0.002. FABP4: HR 2.21, 95% CI 1.12-4.36; p = 0.023) and CV mortality (FABP3: HR 1.28, 95% CI 1.09-1.50; p = 0.002. FABP4: HR 4.19, 95% CI 2.21-7.95; p < 0.001) were only statistically significant in the subgroup of subjects with T2D. Notably, FABP4 (HR 2.07, 95% CI 1.11-3.87; p = 0.022), but not FABP3, also predicted the occurrence of the composite endpoint (death or hospitalization for HF) only in subjects with T2D. All these associations were not found in CHF subjects without T2D. Our findings support the usefulness of serum FABP3 and FABP4 concentrations as independent predictors for the occurrence of all-cause and CV mortality in ambulatory subjects with CHF with T2D.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Can Electronegative LDL Act as a Multienzymatic Complex?

  • Benitez, Sonia|||0000-0003-3565-0743
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Solé, Arnau|||0009-0007-6517-6188
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
Electronegative LDL (LDL(-)) is a minor form of LDL present in blood for which proportions are increased in pathologies with increased cardiovascular risk. In vitro studies have shown that LDL(-) presents pro-atherogenic properties, including a high susceptibility to aggregation, the ability to induce inflammation and apoptosis, and increased binding to arterial proteoglycans; however, it also shows some anti-atherogenic properties, which suggest a role in controlling the atherosclerotic process. One of the distinctive features of LDL(-) is that it has enzymatic activities with the ability to degrade different lipids. For example, LDL(-) transports platelet-activating factor acetylhydrolase (PAF-AH), which degrades oxidized phospholipids. In addition, two other enzymatic activities are exhibited by LDL(-). The first is type C phospholipase activity, which degrades both lysophosphatidylcholine (LysoPLC-like activity) and sphingomyelin (SMase-like activity). The second is ceramidase activity (CDase-like). Based on the complementarity of the products and substrates of these different activities, this review speculates on the possibility that LDL(-) may act as a sort of multienzymatic complex in which these enzymatic activities exert a concerted action. We hypothesize that LysoPLC/SMase and CDase activities could be generated by conformational changes in apoB-100 and that both activities occur in proximity to PAF-AH, making it feasible to discern a coordinated action among them.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A functional virgin olive oil enriched with olive oil and thyme phenolic compounds improves the expression of cholesterol efflux-related genes, A randomized, crossover, controlled trial

  • Farràs Mañé, Marta|||0000-0001-9776-3773
  • Arranz, Sara|||0000-0003-2397-5145
  • Carrión, Silvia|||0000-0002-1354-2488
  • Subirana, Isaac|||0000-0003-1676-0197
  • Muñoz Aguayo, Daniel|||0000-0001-8173-0168
  • Blanchart, Gemma|||0000-0003-1965-8235
  • Kool, Marjon
  • Solà, Rosa|||0000-0002-8359-235X
  • Motilva, María José
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Rubió, Laura
  • Fernández-Castillejo, Sara|||0000-0002-8109-9713
  • Pedret, Anna
  • Estruch, Ramón|||0000-0003-1260-4445
  • Covas Planells, Maria Isabel
  • Fitó, Montserrat|||0000-0002-1817-483X
  • Hernáez, Álvaro|||0000-0001-8593-1477
  • Castañer, Olga|||0000-0003-3169-997X
The consumption of antioxidant-rich foods such as virgin olive oil (VOO) promotes high-density lipoprotein (HDL) anti-atherogenic capacities. Intake of functional VOOs (enriched with olive/thyme phenolic compounds (PCs)) also improves HDL functions, but the gene expression changes behind these benefits are not fully understood. Our aim was to determine whether these functional VOOs could enhance the expression of cholesterol efflux-related genes. In a randomized, double-blind, crossover, controlled trial, 22 hypercholesterolemic subjects ingested for three weeks 25 mL/day of: (1) a functional VOO enriched with olive oil PCs (500 mg/kg); (2) a functional VOO enriched with olive oil (250 mg/kg) and thyme PCs (250 mg/kg; FVOOT), and; (3) a natural VOO (olive oil PCs: 80 mg/kg, control intervention). We assessed whether these interventions improved the expression of cholesterol efflux-related genes in peripheral blood mononuclear cells by quantitative reverse-transcription polymerase chain reactions. The FVOOT intervention upregulated the expression of CYP27A1 (P = 0.041 and P = 0.053, versus baseline and the control intervention, respectively), CAV1 (P = 0.070, versus the control intervention), and LXRβ, RXRα, and PPARβ/δ (P = 0.005, P = 0.005, and P = 0.038, respectively, relative to the baseline). The consumption of a functional VOO enriched with olive oil and thyme PCs enhanced the expression of key cholesterol efflux regulators, such as CYP27A1 and nuclear receptor-related genes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Mechanisms modulating foam cell formation in the arterial intima, exploring new therapeutic opportunities in atherosclerosis

  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Martinez, A.
  • Claudi, Lene
  • Garcia, E.
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Polishchuk, A.
  • Piñero, Janet|||0000-0003-1244-7654
  • Viladés Medel, David|||0000-0002-3638-9703
  • Guerra Ramos, José María|||0000-0001-5397-9177
  • Sanz, F.
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
In recent years, the role of macrophages as the primary cell type contributing to foam cell formation and atheroma plaque development has been widely acknowledged. However, it has been long recognized that diffuse intimal thickening (DIM), which precedes the formation of early fatty streaks in humans, primarily consists of lipid-loaded smooth muscle cells (SMCs) and their secreted proteoglycans. Recent studies have further supported the notion that SMCs constitute the majority of foam cells in advanced atherosclerotic plaques. Given that SMCs are a major component of the vascular wall, they serve as a significant source of microvesicles and exosomes, which have the potential to regulate the physiology of other vascular cells. Notably, more than half of the foam cells present in atherosclerotic lesions are of SMC origin. In this review, we describe several mechanisms underlying the formation of intimal foam-like cells in atherosclerotic plaques. Based on these mechanisms, we discuss novel therapeutic approaches that have been developed to regulate the generation of intimal foam-like cells. These innovative strategies hold promise for improving the management of atherosclerosis in the near future.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Circulating lipoprotein-carried miRNome analysis reveals novel VLDL-enriched microRNAs that strongly correlate with the HDL-microRNA profile

  • Rossi-Herring, Guido|||0000-0003-1454-0916
  • Belmonte, Thalia|||0000-0003-1241-6073
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Benitez, Sonia|||0000-0003-3565-0743
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Crespo García, Javier|||0000-0001-8248-0172
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
Lipoproteins have been described as microRNAs (miRNAs) carriers. Unfortunately, the bibliography on this topic is scarce and shows a high variability between independent investigations. In addition, the miRNA profiles of the LDL and VLDL fractions have not been completely elucidated. Here, we profiled the human circulating lipoprotein-carried miRNome. Lipoprotein fractions (VLDL, LDL and HDL) were isolated from the serum of healthy subjects by ultracentrifugation and purified by size-exclusion chromatography. A panel of 179 miRNAs commonly expressed in circulation was evaluated in the lipoprotein fractions using quantitative real-time PCR (qPCR) assays. A total of 14, 4 and 24 miRNAs were stably detected in the VLDL, LDL and HDL fractions, respectively. VLDL- and HDL-miRNA signatures were highly correlated (rho 0.814), and miR-16-5p, miR-142-3p, miR-223-3p and miR-451a were among the top 5 expressed miRNAs in both fractions. miR-125a-5p, miR-335-3p and miR-1260a, were detected in all lipoprotein fractions. miR-107 and miR-221-3p were uniquely detected in the VLDL fraction. HDL showed the larger number of specifically detected miRNAs (n = 13). Enrichment in specific miRNA families and genomic clusters was observed for HDL-miRNAs. Two sequence motifs were also detected for this group of miRNAs. Functional enrichment analysis including the miRNA signatures from each lipoprotein fraction suggested a potential role in mechanistic pathways previously associated with cardiovascular disease: fibrosis, senescence, inflammation, immune response, angiogenesis, and cardiomyopathy. Collectively, our results not only support the role of lipoproteins as circulating miRNA carriers but also describe for the first time the role of VLDL as a miRNA transporter.